[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 82 of about 82
6. Meyer-Siegler KL, Cox J, Leng L, Bucala R, Vera PL: Macrophage migration inhibitory factor anti-thrombin III complexes are decreased in bladder cancer patient serum: Complex formation as a mechanism of inactivation. Cancer Lett; 2010 Apr 1;290(1):49-57
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Macrophage migration inhibitory factor anti-thrombin III complexes are decreased in bladder cancer patient serum: Complex formation as a mechanism of inactivation.
  • The present study identifies anti-thrombin III (ATIII) as an endogenous MIF binding protein, which reduces MIF biological activity.
  • Serum MIF in bladder cancer patients (TCC stage II, n=50) was increased when compared to normal patients (n=50), while ATIII-MIF complexes were decreased in bladder cancer patient serum.
  • These data suggest that increased circulating levels of bioactive MIF are present in bladder cancer patient serum.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Ireland Ltd.
  • [Cites] Nat Med. 2000 Feb;6(2):164-70 [10655104.001]
  • [Cites] Mediators Inflamm. 2009;2009:535348 [19325914.001]
  • [Cites] Transplantation. 2001 Jun 27;71(12):1777-83 [11455258.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1449-56 [11920501.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4015-20 [12010802.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):2053-63 [12466122.001]
  • [Cites] Trends Cardiovasc Med. 2002 Nov;12(8):331-8 [12536119.001]
  • [Cites] Immunol Cell Biol. 2003 Apr;81(2):137-43 [12631237.001]
  • [Cites] Expert Opin Ther Targets. 2003 Apr;7(2):153-64 [12667094.001]
  • [Cites] J Endotoxin Res. 2003;9(2):119-23 [12803886.001]
  • [Cites] Anal Chem. 2003 Sep 1;75(17):4646-58 [14632076.001]
  • [Cites] J Biol Chem. 2004 Apr 2;279(14):13729-37 [14736878.001]
  • [Cites] BMC Cancer. 2004 Jul 12;4:34 [15248897.001]
  • [Cites] J Urol. 2004 Oct;172(4 Pt 1):1504-9 [15371880.001]
  • [Cites] Am J Clin Pathol. 1978 Feb;69(2):194-5 [629228.001]
  • [Cites] J Clin Pathol. 1979 Jan;32(1):21-5 [429575.001]
  • [Cites] Thromb Haemost. 1981 Aug 28;46(2):500-3 [7302888.001]
  • [Cites] J Urol. 1982 Jul;128(1):72-4 [7109075.001]
  • [Cites] Am J Med. 1989 Sep 11;87(3B):10S-14S [2552799.001]
  • [Cites] Thromb Haemost. 1996 Dec;76(6):897-901 [8972008.001]
  • [Cites] J Biol Chem. 1997 Aug 1;272(31):19393-400 [9235938.001]
  • [Cites] Int J Hematol. 1998 Jul;68(1):67-78 [9713170.001]
  • [Cites] BMC Cancer. 2005;5:73 [16000172.001]
  • [Cites] J Biol Chem. 2005 Nov 4;280(44):36541-4 [16115897.001]
  • [Cites] Eur J Immunol. 2005 Dec;35(12):3405-13 [16224818.001]
  • [Cites] World J Gastroenterol. 2006 Jan 7;12(1):60-5 [16440418.001]
  • [Cites] J Urol. 2006 Apr;175(4):1523-8 [16516040.001]
  • [Cites] J Immunol. 2006 Dec 15;177(12):8730-9 [17142775.001]
  • [Cites] Oncogene. 2007 May 14;26(22):3100-12 [17496909.001]
  • [Cites] Mol Endocrinol. 2007 Jun;21(6):1267-80 [17389748.001]
  • [Cites] Autoimmun Rev. 2007 Nov;7(1):8-11 [17967718.001]
  • [Cites] Electrophoresis. 2007 Dec;28(23):4302-10 [18041032.001]
  • [Cites] Intensive Care Med. 2008 Feb;34(2):361-7 [17940748.001]
  • [Cites] Inflamm Res. 2008 Feb;57(2):45-50 [18288453.001]
  • [Cites] J Cell Physiol. 2008 Jun;215(3):665-75 [18064633.001]
  • [Cites] Oncology. 2008;75(3-4):127-33 [18791328.001]
  • [Cites] J Clin Invest. 2008 Nov;118(11):3533-6 [18982159.001]
  • [Cites] J Cell Biochem. 2008 Dec 1;105(5):1279-88 [18821572.001]
  • [Cites] Mol Cell Biol. 2009 Apr;29(7):1922-32 [19188446.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1117-23 [10666179.001]
  • (PMID = 19762145.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R21 DK075059; United States / NIAID NIH HHS / AI / R01 AI042310-06; United States / NIDDK NIH HHS / DK / DK075059; United States / NIAID NIH HHS / AI / R01 AI042310; United States / NIDDK NIH HHS / DK / DK075059-02; United States / NIDDK NIH HHS / DK / R21 DK075059-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Macrophage Migration-Inhibitory Factors; 0 / Multiprotein Complexes; 9000-94-6 / Antithrombin III
  • [Other-IDs] NLM/ NIHMS146096; NLM/ PMC2832085
  •  go-up   go-down


7. Biondo S, Kreisler E, Millan M, Martí-Ragué J, Fraccalvieri D, Golda T, De Oca J, Osorio A, Fradera R, Salazar R, Rodriguez-Moranta F, Sanjuán X: [Long-term results of emergency surgery for colon cancer compared with elective surgery]. Cir Esp; 2007 Aug;82(2):89-98

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term results of emergency surgery for colon cancer compared with elective surgery].
  • [Transliterated title] Resultados a largo plazo de la cirugía urgente y electiva del cáncer de colon. Estudio comparativo.
  • AIMS: The aim of the present study was to analyze the 5-year efficacy of curative oncological surgery for complicated colon cancer performed in an emergency setting in terms of tumor recurrence and survival compared with elective surgery of uncomplicated tumors.
  • PATIENTS AND METHOD: We performed a prospective observational cohort study in patients who underwent emergency surgery for complicated colon cancer (group 1) and patients who underwent elective surgery (group 2).
  • Exclusion criteria were tumors of less than 15 cm from the anal verge, palliative surgery, and distant metastases.
  • Significant differences were found in disease stage between the 2 groups (P = 0.003).
  • When patients were stratified by TNM stage, worse 5-year cancer-related and disease-free survival rates were observed in group 1 patients with stage II tumors.
  • No differences were found in cancer-related survival rates in stage III patients (P = 0.178).
  • There were no significant differences in overall survival, cancer-related survival or tumor recurrence rates when group 1 was compared with a subgroup of patients in group 2 with factors of poor prognosis.
  • CONCLUSIONS: Complicated colon cancer presents in more advanced stages and had a worse overall long-term prognosis than uncomplicated tumour.
  • These differences decrease when patients are subclassified by tumoral stage.
  • Overall survival and cancer-related survival rates similar to those of elective surgery can be achieved in emergency surgery when curative oncological resection is performed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17785142.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


8. Nguyen BT, Joon DL, Khoo V, Quong G, Chao M, Wada M, Joon ML, See A, Feigen M, Rykers K, Kai C, Zupan E, Scott A: Assessing the impact of FDG-PET in the management of anal cancer. Radiother Oncol; 2008 Jun;87(3):376-82
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing the impact of FDG-PET in the management of anal cancer.
  • PURPOSE: To assess the utility of FDG-PET in anal cancer for staging and impact on radiotherapy planning (RTP), response and detection of recurrent disease.
  • METHODS AND MATERIALS: Fifty histopathological anal cancer patients were reviewed between 1996 and 2006.
  • RESULTS: The non-PET staging was Stage I(8), Stage II(18), Stage III(22), and Stage IV(2)s.
  • CONCLUSIONS: Anal cancer is FDG-PET avid.
  • PET can aid in anal cancer staging and identification of residual disease, recurrent/metastatic disease but warrants further prospective studies.
  • [MeSH-major] Anus Neoplasms / radionuclide imaging. Carcinoma, Squamous Cell / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18453023.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


9. Fujita S, Yamamoto S, Akasu T, Moriya Y: Outcome of patients with clinical stage II or III rectal cancer treated without adjuvant radiotherapy. Int J Colorectal Dis; 2008 Nov;23(11):1073-9
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients with clinical stage II or III rectal cancer treated without adjuvant radiotherapy.
  • BACKGROUND: To clarify the indications for preoperative adjuvant radiotherapy for rectal cancer, the outcome of patients who underwent curative surgery without adjuvant radiotherapy was investigated.
  • METHODS: A total of 817 consecutive patients who underwent curative surgery for clinical stage II or III rectal cancer without preoperative adjuvant radiotherapy between 1988 and 2002 were reviewed.
  • Univariate analysis showed that sex, pathological T classification (pT), clinical N classification (cN), pathological N classification (pN), tumor site, distance from the anal verge, type of surgery, pathological stage, a positive radical margin, lymphatic invasion, and venous invasion were significantly correlated with local recurrence.
  • Multivariate analysis of preoperative factors identified cN, distance from the anal verge, and sex as statistically significant risk factors for local recurrence.
  • In patients with rectal cancer located less than 5 cm from the anal verge and with positive cN, the local recurrence rate was more than 10%.
  • CONCLUSIONS: Patients with rectal cancer located less than 5 cm from the anal verge and with clinically positive lymph nodes should be given preoperative adjuvant radiotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Colorectal Dis. 2006 Jan;8(1):34-6 [16519635.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4620-5 [17008704.001]
  • [Cites] Dis Colon Rectum. 2006 Mar;49(3):345-52 [16532369.001]
  • [Cites] Dis Colon Rectum. 2007 Feb;50(2):156-67 [17180256.001]
  • [Cites] Semin Oncol. 2006 Dec;33(6 Suppl 11):S64-9 [17178291.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1847-58 [15774778.001]
  • [Cites] Dis Colon Rectum. 2005 Feb;48(2):218-26 [15711860.001]
  • [Cites] N Engl J Med. 2006 Sep 14;355(11):1114-23 [16971718.001]
  • [Cites] Br J Surg. 1982 Oct;69(10):613-6 [6751457.001]
  • [Cites] Dis Colon Rectum. 2006 Sep;49(9):1266-74 [16915510.001]
  • [Cites] Br J Surg. 2007 Oct;94(10):1278-84 [17579345.001]
  • [Cites] Ann Surg. 2005 Oct;242(4):502-10; discussion 510-1 [16192810.001]
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):411-23 [15875292.001]
  • [Cites] Br J Surg. 2006 Dec;93(12):1519-25 [17054311.001]
  • [Cites] Radiology. 2003 May;227(2):371-7 [12732695.001]
  • [Cites] Br J Surg. 2003 Dec;90(12):1580-5 [14648739.001]
  • [Cites] Semin Oncol. 2006 Dec;33(6 Suppl 11):S70-4 [17178292.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8697-705 [16314629.001]
  • [Cites] Dis Colon Rectum. 2006 May;49(5):557-67 [16550319.001]
  • [Cites] Br J Surg. 2006 Oct;93(10):1215-23 [16983741.001]
  • [Cites] Br J Surg. 2006 Jul;93(7):860-5 [16710878.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):449-57 [11923599.001]
  • [Cites] Eur J Surg Oncol. 2006 Jun;32(5):520-6 [16600560.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):6199-206 [16135487.001]
  • [Cites] Lancet. 1994 Sep 10;344(8924):707-11 [7915774.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):83-90 [17592295.001]
  • [Cites] Lancet. 1986 Nov 1;2(8514):996-9 [2430152.001]
  • (PMID = 18594841.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


10. Widder J, Kastenberger R, Fercher E, Schmid R, Langendijk JA, Dobrowsky W, Pötter R: Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients. Radiother Oncol; 2008 Jun;87(3):367-75
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients.
  • BACKGROUND AND PURPOSE: To retrospectively analyse a large consecutive cohort of patients with anal cancer for treatment-related factors influencing local control and survival.
  • MATERIALS AND METHODS: All patients referred for primary radiotherapy at Medical University of Vienna in 1990-2002 with anal canal carcinoma without distant metastases were analysed.
  • RESULTS: Median age was 67 years (n=129), the UICC stage distribution was 15%, 58%, and 27% for stages I, II, and III, respectively.
  • Stage and age were significant factors for overall and colostomy-free-survival, N-stage for disease-free-survival.
  • Shorter overall treatment time favoured local control in stage T1-2 (p=.015), higher total radiation dose and female gender were associated with improved local control in T3-4 tumours (p=.021).
  • CONCLUSIONS: These results support potential improvement of anal cancer treatment by studying advanced technology such as IMRT, making it possible to tailor high-dose regions.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18501453.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


11. Takashima A, Shimada Y, Hamaguchi T, Ito Y, Masaki T, Yamaguchi S, Kondo Y, Saito N, Kato T, Ohue M, Higashino M, Moriya Y, Colorectal Cancer Study Group of the Japan Clinical Oncology Group: Current therapeutic strategies for anal squamous cell carcinoma in Japan. Int J Clin Oncol; 2009 Oct;14(5):416-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current therapeutic strategies for anal squamous cell carcinoma in Japan.
  • BACKGROUND: In Western countries, chemoradiotherapy (CRT) is well established as the standard therapy for stages II/III anal squamous cell carcinoma (ASCC).
  • The Colorectal Cancer Study Group of the Japan Clinical Oncology Group (JCOG-CCSG) conducted a survey to determine the current therapeutic strategies for ASCC in Japan.
  • The target subjects were patients with stages II/III ASCC, diagnosed from January 2000 to December 2004, who were 20-80 years of age with normal major organ function and no severe complications.
  • Detailed information was obtained for 55 subjects; 25 (45%) had stage II ASCC and 30 (55%) had stage III ASCC.
  • The 3-year progression-free survival rates for all subjects and for CRT-only subjects were 67% and 77%, respectively.
  • [MeSH-major] Anus Neoplasms / therapy. Asian Continental Ancestry Group. Carcinoma, Squamous Cell / therapy. Digestive System Surgical Procedures

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 1994 Mar;8(3):283-95 [8031509.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] Cancer. 1983 Apr 1;51(7):1291-6 [6825051.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):575-81 [9261527.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] J Natl Cancer Inst. 1989 Jun 7;81(11):850-6 [2724350.001]
  • [Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3121-5 [8955657.001]
  • [Cites] Surg Oncol. 2005 Nov;14(3):121-32 [16165347.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1195-202 [12599225.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Br J Surg. 1989 Aug;76(8):806-10 [2765832.001]
  • (PMID = 19856049.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Japan
  • [Investigator] Kondo Y; Ohtsuka K; Shiiba K; Sato T; Yoshimi F; Kotake K; Sawada T; Mochizuki H; Konishi F; Saito N; Moriya Y; Masaki T; Aoki T; Takahashi K; Hasegawa H; Kenichi S; Sumiyama Y; Sato T; Akaike M; Kudo S; Yamada T; Munakata Y; Shigeski Y; Kato T; Maeda K; Koizumi K; Monden M; Ohue M; Higashino M; Tanigawa M; Fukunaga M; Kato T; Okamura S; Kimura H; Okajima M; Takakura N; Tanada M; Shirouzu K; Kitano S
  •  go-up   go-down


12. Bilimoria KY, Bentrem DJ, Rock CE, Stewart AK, Ko CY, Halverson A: Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum; 2009 Apr;52(4):624-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base.
  • PURPOSE: The objective of this study was to assess survival and prognostic factors for anal carcinoma in the population.
  • METHODS: Patients with squamous-cell carcinoma of the anal canal were identified from the National Cancer Data Base (1985-2000).
  • Concordance was calculated to assess agreement between American Joint Committee on Cancer stage and actual outcome.
  • RESULTS: Nineteen thousand one hundred ninety-nine patients with anal carcinoma were identified (Stage I, 25.3 percent; Stage II, 51.8 percent; Stage III, 17.1 percent; Stage IV, 5.7 percent).
  • The American Joint Committee on Cancer (6th edition) staging system provided good survival discrimination by stage: I, 69.5 percent; II, 59.0 percent; III, 40.6 percent; and IV, 18.7 percent (concordance index, 0.663).
  • On multivariable analysis, patients with anal carcinoma had a higher risk of death if they were male, >or=65 years old, black, living in lower median incomes areas, and had more advanced T stage tumors, nodal or distant metastases, or poorly differentiated cancers (P < 0.0001).
  • CONCLUSION: Although tumor characteristics and staging affect prognosis, patient factors, such as gender, race, and socioeconomic status, are also important prognostic factors for squamous-cell carcinoma of the anal canal.
  • [MeSH-major] Anus Neoplasms / mortality. Carcinoma, Squamous Cell / mortality

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404066.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Habr-Gama A, Perez RO, Nadalin W, Nahas SC, Ribeiro U Jr, Silva E Sousa AH Jr, Campos FG, Kiss DR, Gama-Rodrigues J: Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival. J Gastrointest Surg; 2005 Jan;9(1):90-9; discussion 99-101
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
  • Neoadjuvant chemoradiation treatment (CRT) has resulted in significant tumor downstaging and improved local disease control for distal rectal cancer.
  • The purpose of the present study was to determine the correlation between final stage and survival in these patients regardless of initial disease stage.
  • Two hundred sixty patients with distal (0-7 cm from anal verge) rectal adenocarcinoma considered resectable were treated by neoadjuvant CRT with 5-FU and leucovorin plus 5040 cGy.
  • Overall survival and disease-free survival were compared according to Kaplan-Meier curves and log-rank tests according to final stage.
  • Seventy-one patients (28%) showed complete clinical response (clinical stage 0).
  • In 22 of these patients (9%), pathologic examination revealed pT0 N0 M0 (stage p0), 59 patients (22%) had stage I, 68 patients (26%) had stage II, and 40 patients (15%) had stage III disease.
  • Overall survival rates were significantly higher in stage c0 (P=0.01) compared with stage p0.
  • Disease-free survival rate showed better results in stage c0, but the results were not significant.
  • Five-year overall and disease-free survival rates were 97.7% and 84% (stage 0); 94% and 74% (stage I); 83% and 50% (stage II); and 56% and 28% (stage III), respectively.
  • Cancer-related overall and disease-free survival may be correlated to final pathologic staging following neoadjuvant CRT for distal rectal cancer.
  • Also, stage 0 is significantly associated with improved outcome.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1993 Feb 20;341(8843):457-60 [8094488.001]
  • [Cites] Br J Surg. 2003 Aug;90(8):999-1003 [12905555.001]
  • [Cites] J Gastrointest Surg. 2004 Jan;8(1):56-62; discussion 62-3 [14746836.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1027-38 [10421535.001]
  • [Cites] Eur J Surg Oncol. 2001 Jun;27(4):349-53 [11417978.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Rev Invest Clin. 2001 Sep-Oct;53(5):388-95 [11795103.001]
  • [Cites] J Natl Cancer Inst. 1988 Mar 2;80(1):21-9 [3276900.001]
  • [Cites] Rev Invest Clin. 2001 Jan-Feb;53(1):65-76 [11332053.001]
  • [Cites] Br J Surg. 2001 Jul;88(7):988-93 [11442533.001]
  • [Cites] World J Surg. 2001 Aug;25(8):1006-11 [11571965.001]
  • [Cites] Br J Surg. 1986 Sep;73(9):732-5 [3756437.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):1121-30 [11920483.001]
  • [Cites] Lancet. 1986 Jun 28;1(8496):1479-82 [2425199.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):935-41 [9869213.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1417-24 [7751887.001]
  • [Cites] Dis Colon Rectum. 1997 May;40(5):515-22 [9152176.001]
  • [Cites] Dis Colon Rectum. 2001 Aug;44(8):1123-8 [11535851.001]
  • [Cites] Dis Colon Rectum. 2000 Dec;43(12):1695-1701; discussion 1701-3 [11156453.001]
  • [Cites] Radiother Oncol. 1999 May;51(2):153-60 [10435807.001]
  • [Cites] J Surg Oncol. 2003 Jul;83(3):133-9 [12827680.001]
  • [Cites] Arch Surg. 2002 Feb;137(2):206-10 [11822961.001]
  • [Cites] Cancer. 1994 Feb 1;73(3):563-9 [7507795.001]
  • [Cites] J Am Coll Surg. 2002 Feb;194(2):131-5; discussion 135-6 [11848629.001]
  • [Cites] Dis Colon Rectum. 2004 Mar;47(3):279-86 [14991488.001]
  • [Cites] Dis Colon Rectum. 1998 Sep;41(9):1087-96 [9749491.001]
  • [Cites] J Pathol. 1994 Feb;172(2):183-7 [7513353.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Apr 1;41(1):21-7 [9588913.001]
  • [Cites] Dis Colon Rectum. 1997 Feb;40(2):131-9 [9075745.001]
  • (PMID = 15623449.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


1
Advertisement
4. Pucciarelli S, Capirci C, Emanuele U, Toppan P, Friso ML, Pennelli GM, Crepaldi G, Pasetto L, Nitti D, Lise M: Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer. Ann Surg Oncol; 2005 Feb;12(2):111-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer.
  • BACKGROUND: We investigated the relationship between pathologic T-stage and mesorectal metastases after preoperative chemoradiotherapy (CRT) for clinical stage II to III rectal carcinoma.
  • METHODS: The records of consecutive patients with clinical stage II to III carcinoma of the mid or low rectum who underwent surgery after CRT were reviewed.
  • Indications for preoperative CRT were cancer up to 11 cm from the anal verge, Eastern Cooperative Oncology Group performance status of 0 to 2, age 18 to 75 years, and clinical tumor-node-metastasis stage II or III.
  • The pretreatment tumor-node-metastasis stage was as follows: I, n = 1; II, n = 96; and III, n = 138.
  • According to the pT stage, the rate of node positivity was 2% for pT0, 15% for pT1, 17% for pT2, 38% for pT3, and 33% for pT4 cases.
  • On considering pT stage alone, the odds ratio was in the region of 10 for pT1/2 and >20 for pT3/4 patients.
  • CONCLUSIONS: In patients with pT0 after preoperative CRT for clinical stage II to III mid or low rectal cancer, the risk of nodal metastases is very low.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2005 Feb;12(2):95-7 [15827785.001]
  • (PMID = 15827790.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


15. Velenik V, Ocvirk J, Oblak I, Anderluh F: Neoadjuvant cetuximab, capecitabine, and radiotherapy (RT) in locally advanced resectable rectal cancer: results of a phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):e15029

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant cetuximab, capecitabine, and radiotherapy (RT) in locally advanced resectable rectal cancer: results of a phase II trial.
  • : e15029 Background: Preoperative chemoradiotherapy (CRT) with capecitabine is a treatment of choice for locally advanced rectal cancer.
  • The aim of this prospective, nonrandomized, open-label phase II study was to establish the efficacy and safety profile of cetuximab combined with capecitabine and concurrent RT for locally advanced resectable rectal cancer.
  • METHODS: Patients (pts) with stage II or III rectal cancer confirmed by MRI were treated with capecitabine 1250 mg/m<sup>2</sup> twice daily for 2 weeks.
  • The median tumor distance from anal verge was 6 (range: 1-11) cm.
  • The total sphincter preservation rate was 75.7%; in 17 pts whose tumors were located ≤5 cm of the anal verge, the rate was 53%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964401.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Roohipour R, Patil S, Goodman KA, Minsky BD, Wong WD, Guillem JG, Paty PB, Weiser MR, Neuman HB, Shia J, Schrag D, Temple LK: Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum; 2008 Feb;51(2):147-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous-cell carcinoma of the anal canal: predictors of treatment outcome.
  • PURPOSE: The incidence of anal canal squamous-cell carcinoma is increasing.
  • METHODS: Using one database, we identified 131 Stages I-III patients treated for primary anal canal squamous-cell carcinoma at our institution from December 1986 to August 2006, with minimum six-month follow-up.
  • RESULTS: Of 131 patients (median age, 58.3 years; median follow-up, 2.9 (range, 0.6-11.2) years), 66 percent were females, 43.5 percent were Stage II, and 11 (8 percent) were HIV-positive.
  • Almost all patients undergoing radiotherapy (96.7 percent, 118/122) also had chemotherapy: 118 (100 percent, Stages I-III) had concurrent chemotherapy: (98 (83.8 percent) mitomycin/5-fluorouracil, 12 (10.2 percent) cisplatin/5-fluorouracil, 8 (6.8 percent) 5-fluorouracil alone); 35 of 46 (76 percent) Stage III patients received induction chemotherapy (34 (97.1 percent) cisplatin/5-fluorouracil, 1 (2.8 percent) 5-fluorouracil alone).
  • Many (44 percent Stages I/II, 48.9 percent Stage III) required dose adjustments.
  • Bivariate analyses demonstrated that T stage (P=0.0019), completion of radiotherapy, and total radiotherapy dose (P=0.03) were all significantly associated with treatment failure.
  • On multivariate analyses, disease stage (P=0.05) and completion of radiotherapy (P=0.01) remained significant predictors of relapse-free survival.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Dis Colon Rectum. 2008 May;51(5):620
  • (PMID = 18180997.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


17. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, Halverson AL: Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States. Ann Surg Oncol; 2008 Jul;15(7):1948-58
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States.
  • BACKGROUND: Over the past two decades, recommended treatment for squamous cell carcinoma of the anal canal has shifted from surgery to primary chemoradiation.
  • METHODS: From the National Cancer Data Base (1985-2005), 38,882 patients with anal canal cancer were identified.
  • Patients were significantly less likely to receive guideline treatment if male, older, black or Hispanic, more severe comorbidities, or Stage I (vs Stage II or III).
  • [MeSH-major] Anus Neoplasms / therapy. Neoplasms, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18414951.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


18. Selvindos PB, Ho YH: Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis. Dis Colon Rectum; 2008 Nov;51(11):1710-1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis.
  • PURPOSE: Optimal treatment of mid to distal rectal cancers includes total mesorectal excision for oncologic clearance and, where reanastomosis is feasible, a colonic J-pouch-anal anastomosis improves bowel function.
  • Bowel continuity was restored by an intracoporeal double-cross stapled colonic J-pouch-anal anastomosis, but where not possible a coloplasty with pull-through handsewn coloanal anastomosis was performed.
  • Ten patients (18 percent) had an American Society of Anesthesiologists' classification of III.
  • The indications were adenocarcinoma (n = 51), squamous-cell carcinoma of rectum (n = 1), dermoid tumor of mesorectum (n = 1), large villous adenoma (n = 1), and carcinoid with local lymph node metastases (n = 1).
  • The adenocarcinomas were a median distance of 6 (3-12) cm from the anal verge.
  • The histologic grading or the adenocarcinoma patients were: Stage I, n = 14; Stage II, n = 23; Stage III, n = 11; Stage IV, n = 3.
  • Of those who underwent curative resection (Stages I-III), the distal resection margin was 2.9 +/- 0.7 cm (mean +/- standard error) and the radial resection margins were at least 2 mm in all patients.
  • The level of the coloanal anastomosis was a median 3.5 (0-4.5) cm from the anal verge; a coloanal pull-through anastomosis was required in one patient who had a distal cancer.
  • Four other patients had smaller pelvic collections that resolved with antibiotics; pelvic collections were associated with advanced stage of cancer (P = 0.047).
  • This brought the rectum proximally and anteriorly, aiding with the laparoscopic stapler transection of the distal rectum, especially if the cancer was distal, the patient was obese, and the pelvis was narrow.
  • Further randomized, controlled studies that include assessing five-year cancer survival/recurrence, pelvic nerve dysfunction, and bowel function are needed before laparoscopic ultralow anterior resection becomes widely accepted.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Colonic Pouches. Laparoscopy / methods. Proctocolectomy, Restorative / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18679748.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Interactive Tutorial
  • [Publication-country] United States
  •  go-up   go-down


19. Piperkova E, Raphael B, Altinyay M, Castellon I, Libes R, Sandella N, Abdel-Dayem H: Impact of PET/CT on initial staging, restaging and treatment management of anal cancer: a clinical case with literature review. J BUON; 2006 Oct-Dec;11(4):523-7
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of PET/CT on initial staging, restaging and treatment management of anal cancer: a clinical case with literature review.
  • Distant extrapelvic metastases appear in approximately in 10% of the patients with squamous cell anal cancer (SCAC) and survival depends on the treatment strategy.
  • We present a patient with SCAC in whom, according to PET/CT findings, the initial stage was changed from II (T2N0M0) to III A (T2N2M0).
  • Radiation therapy (RT) and chemotherapy achieved a good therapeutic response but early follow up revealed new paraaortic lymph node (LN) metastases, as well as an uncommon left supraclavicular LN metastasis from the same primary carcinoma.
  • The disease was restaged as stage IV (T2N2M1) and radiation therapy was substituted by chemotherapy.
  • [MeSH-major] Anus Neoplasms / radiography. Anus Neoplasms / radionuclide imaging. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17309188.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


20. Fallai C, Cerrotta A, Valvo F, Badii D, Olmi P: Anal carcinoma of the elderly treated with radiotherapy alone or with concomitant radio-chemotherapy. Crit Rev Oncol Hematol; 2007 Mar;61(3):261-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma of the elderly treated with radiotherapy alone or with concomitant radio-chemotherapy.
  • PURPOSE: To analyse the results achieved with radio-chemotherapy (RTCT) or radiotherapy alone (RT) in elderly patients (pts) affected with squamous cell anal cancer.
  • There were 9 stage I, 29 stage II, 11 stage IIIa and 13 stage IIIb.
  • RESULTS: Stage II fared significantly better than stage III in terms of locoregional control (LRC) but not overall survival (OS).
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17085056.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


21. Temple LK, Romanus D, Niland J, Veer AT, Weiser MR, Skibber J, Wilson J, Rajput A, Benson A, Wong YN, Schrag D: Factors associated with sphincter-preserving surgery for rectal cancer at national comprehensive cancer network centers. Ann Surg; 2009 Aug;250(2):260-7
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors associated with sphincter-preserving surgery for rectal cancer at national comprehensive cancer network centers.
  • OBJECTIVE: To determine rate and predictors of sphincter-preserving surgery (SPS) for rectal cancer patients treated at specialty institutions.
  • Evidence of association between case volume and SPS rate has prompted recommendations that all rectal cancer patients undergo surgery at specialty institutions.
  • METHODS: A prospective registry of all colorectal cancer patients treated at 7 National Comprehensive Cancer Network institutions was used to identify patients with clinical stage I-III rectal cancer undergoing surgery (n = 674) between September 2005 and October 2007.
  • CONCLUSIONS: SPS rates at National Comprehensive Cancer Network institutions exceed those seen in population-based samples and clinical trials.
  • [MeSH-major] Anal Canal. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19638922.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


22. Li SY, Liang ZJ, Yuan SJ, Yu B, Chen G, Zuo FY, Bai X, Chen G, Wei XJ, Xu YS, Cui W: [Clinical experience of 371 cases of sphincter-preservation with telescopic anastomosis after radical excision for low-middle rectal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Apr;13(4):263-5
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical experience of 371 cases of sphincter-preservation with telescopic anastomosis after radical excision for low-middle rectal cancer].
  • OBJECTIVE: To evaluate the clinical efficacy, feasibility and safety of sphincter-preservation with telescopic anastomosis of colon and rectal mucosa in low-middle rectal cancer.
  • METHODS: A retrospective analysis was carried out in 371 patients with low-middle rectal cancer in whom telescopic anastomosis was used.
  • The lower margins of the tumors located between 5-8 cm from the anal verge.
  • According to the Duke's stage classification, 120 were TNM stage I, 222 stage II, 26 stage III, and 3 stage IV.
  • CONCLUSION: The sphincter-preservation with telescopic anastomosis procedure is safe and effective for low-middle rectal cancer, and the sphincter function can be well-preserved.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Anastomosis, Surgical / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20422480.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


23. Lupattelli M, Mascioni F, Bellavita R, Draghini L, Tarducci R, Castagnoli P, Russo G, Aristei C: Long-term anorectal function after postoperative chemoradiotherapy in high-risk rectal cancer patients. Tumori; 2010 Jan-Feb;96(1):34-41
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term anorectal function after postoperative chemoradiotherapy in high-risk rectal cancer patients.
  • AIMS AND BACKGROUND: After sphincter-preserving surgery for rectal cancer and postoperative radiochemotherapy, many patients have unsatisfactory anorectal functional results which are not considered by the most common toxicity scales.
  • The aim of the present study was to retrospectively assess the long-term incidence of impaired anorectal function in rectal cancer patients who underwent anterior resection and postoperative radiochemotherapy.
  • METHODS: Ninety-nine patients who underwent sphincter-saving surgery and postoperative radiochemotherapy for stage II-III rectal cancer from July 1991 to January 2002 were given a questionnaire on anorectal function.
  • [MeSH-major] Anal Canal / physiopathology. Rectal Neoplasms / therapy. Rectum / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20437855.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


24. Hosein PJ, Rocha-Lima CM: Role of combined-modality therapy in the management of locally advanced rectal cancer. Clin Colorectal Cancer; 2008 Nov;7(6):369-75
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of combined-modality therapy in the management of locally advanced rectal cancer.
  • The majority of patients with nonmetastatic rectal cancer are candidates for an aggressive multimodality approach with curative intent.
  • Multidisciplinary preoperative patient evaluation, better staging techniques, neoadjuvant chemoradiation, acceptance of shorter distal rectal margins, and transanal excision of T1 N0 rectal tumors in close proximity to the anal sphincter have resulted in decreased rates of abdominoperineal resections.
  • Preoperative and postoperative radiation therapy was shown to decrease the local recurrence rate, but not overall survival, in patients with resectable rectal cancer.
  • For patients with stage II or III disease, neoadjuvant continuous-infusion 5-fluorouracil (5-FU), concurrently with pelvic radiation, followed by postoperative 5-FU-based chemotherapy, remains the standard multimodality approach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19036689.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 59
  •  go-up   go-down


25. Staudacher C, Di Palo S, Tamburini AM, Vignali A, Orsenigo E: [The role of neoadjuvant radio-chemotherapy in the treatment of rectal cancer]. Ann Ital Chir; 2007 Nov-Dec;78(6):493-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of neoadjuvant radio-chemotherapy in the treatment of rectal cancer].
  • [Transliterated title] Il ruolo della radiochemioterapia neoadiuvante nel trattamento del tumore del retto.
  • OBJECTIVE: To evaluate oncological and surgical outcome of patients submitted to neoadjuvant therapy for advanced rectal cancer.
  • PATIENTS AND METHOD: One hundred thirty eight patients (86 male, 52 female, mean age 61.4 years), with tumour of lower (58; 42%), middle (66; 48%), upper rectum (14; 10%), showing a clinical stage II (23; 17%) or III (115; 83%) and with an average distance from anal verge of 6.5 cm, submitted to fractionated "long-course" RT with CT locally staged by US and MR before and after neoadjuvant therapy and operated on after 4-6 weeks by its end.
  • Pre-treatment clinical stage was not significant.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18510028.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


26. Ceelen W, Boterberg T, Pattyn P, van Eijkeren M, Gillardin JM, Demetter P, Smeets P, Van Damme N, Monsaert E, Peeters M: Neoadjuvant chemoradiation versus hyperfractionated accelerated radiotherapy in locally advanced rectal cancer. Ann Surg Oncol; 2007 Feb;14(2):424-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemoradiation versus hyperfractionated accelerated radiotherapy in locally advanced rectal cancer.
  • BACKGROUND: Neoadjuvant therapy is increasingly used in resectable locally advanced rectal cancer.
  • METHODS: Clinical, pathological, and survival data were obtained from patients with resectable stage II or III rectal cancer within 7 cm from the anal verge.
  • The mean distance from the anal verge was 5.8 cm (HART) versus 4.9 cm (CRT).

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17096057.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Ballonoff A, Kavanagh B, McCarter M, Kane M, Pearlman N, Nash R, Shah RJ, Raben D, Schefter TE: Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial. Am J Clin Oncol; 2008 Jun;31(3):264-70
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial.
  • OBJECTIVES: A prospective phase II trial was conducted to evaluate the feasibility, safety, and pathologic response rate of preoperative capecitabine and accelerated synchronous integrated boost (SIB) intensity-modulated radiotherapy (IMRT) in patients with locally advanced rectal cancer.
  • METHODS: Consenting operable patients with stage II or III adenocarcinoma of the rectum received capecitabine (825 mg/m2 PO BID, 5 days/wk x 5 weeks) and SIB-IMRT delivering 55 Gy (2.2 Gy/fraction) to the gross tumor while simultaneously delivering 45 Gy (1.8 Gy/fraction) to the regional lymph nodes and areas at risk for harboring microscopic disease.
  • A single pathologist analyzed the resected tumor's TNM stage and Mandard regression/response scores.
  • Of 3 patients who had tumors within 5 cm of the anal verge, 2 underwent sphincter-sparing procedures.
  • CONCLUSIONS: Preoperative chemoradiation with capecitabine and SIB-IMRT is well tolerated and results in an encouraging pCR rate for patients with locally advanced rectal cancer.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18525306.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


28. Yamada K, Ogata S, Saiki Y, Fukunaga M, Tsuji Y, Takano M: Long-term results of intersphincteric resection for low rectal cancer. Dis Colon Rectum; 2009 Jun;52(6):1065-71
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of intersphincteric resection for low rectal cancer.
  • PURPOSE: Intersphincteric resection has been performed as an alternative to abdominoperineal resection for low rectal cancer.
  • METHODS: Between 1994 and 2006, 107 consecutive patients with low rectal cancer had curative intersphincteric resection, categorized as total, subtotal, or partial resection of the internal anal sphincter.
  • The five-year disease-free survival rates classified according to the TNM stage were 100 percent for stage I, 83.5 percent for stage II, and 72.0 percent for stage III cases.
  • CONCLUSION: Provided strict selection criteria are used, intersphincteric resection may be the optimal sphincter-preserving surgery for low rectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19581848.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Fukunaga Y, Higashino M, Tanimura S, Takemura M, Fujiwara Y: Laparoscopic rectal surgery for middle and lower rectal cancer. Surg Endosc; 2010 Jan;24(1):145-51
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic rectal surgery for middle and lower rectal cancer.
  • BACKGROUND: The usefulness of laparoscopic low anterior resection for middle and lower rectal cancer remains controversial.
  • METHODS: Retrospective assessment was performed on 98 patients (51 with middle and 47 with lower rectal cancer) who underwent laparoscopic rectal surgery since 1998.
  • Cancers were classified as middle or lower rectal based on distance from the distal tumor border to the anal verge (<8 cm or >or=8 cm).
  • The 5-year disease-free/overall survival rates were 82.3/95.7% in stage I, 55.1/72.0% in stage II, and 59.5/80.7% in stage III.
  • It is a useful option even for advanced lower rectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Endosc. 2010 Dec;24(12):3241-3 [20372934.001]
  • [Cites] Br J Surg. 1994 May;81(5):648-52 [8044537.001]
  • [Cites] Arch Surg. 1998 Aug;133(8):894-9 [9711965.001]
  • [Cites] Surg Laparosc Endosc. 1991 Sep;1(3):144-50 [1688289.001]
  • [Cites] Dis Colon Rectum. 1993 Sep;36(9):858-61 [8397078.001]
  • [Cites] Hepatogastroenterology. 2007 Jan-Feb;54(73):85-90 [17419237.001]
  • [Cites] Br J Surg. 1985 Aug;72(8):599-601 [4027529.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1124-32 [15997446.001]
  • [Cites] Ann Surg. 2001 Aug;234(2):190-7 [11505064.001]
  • [Cites] Dis Colon Rectum. 2008 Jun;51(6):844-51 [18330644.001]
  • [Cites] Br J Surg. 1996 Feb;83(2):214-6 [8689166.001]
  • [Cites] J Am Coll Surg. 2001 Nov;193(5):579-84 [11708519.001]
  • [Cites] World J Surg. 2008 Sep;32(9):2095-100 [18612681.001]
  • [Cites] Br J Surg. 2003 Jul;90(7):867-71 [12854115.001]
  • [Cites] Surgery. 1994 Nov;116(5):842-6 [7940187.001]
  • [Cites] Br J Surg. 1999 Dec;86(12):1532-7 [10594501.001]
  • [Cites] Ann Surg. 2003 Mar;237(3):335-42 [12616116.001]
  • [Cites] Surg Endosc. 1996 Aug;10(8):809-12 [8694943.001]
  • [Cites] Acta Chir Belg. 1994 Sep-Oct;94(5):258-62 [7976066.001]
  • [Cites] Ann Surg. 2008 Apr;247(4):627-32 [18362625.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):315-21 [11289275.001]
  • [Cites] Surg Endosc. 2004 Feb;18(2):281-9 [14691716.001]
  • [Cites] Am J Surg. 1982 Sep;144(3):350-4 [7114377.001]
  • [Cites] Br J Surg. 1998 Apr;85(4):526-9 [9607540.001]
  • (PMID = 19517172.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


30. Pasetto LM, Basso U, Sinigaglia G, Pucciarelli S, Friso ML, Rugge M, Toppan P, Agostini M, Monfardini S: Rectal cancer adjuvant chemotherapy: when is more useful? Anticancer Res; 2008 May-Jun;28(3B):1805-12
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rectal cancer adjuvant chemotherapy: when is more useful?
  • THE AIM of the study was to evaluate time-to-progression (TTP) of rectal cancer in a group of patients receiving adjuvant chemotherapy (CHT) after combined neoadjuvant treatment.
  • PATIENTS AND METHODS: From January 2000 to December 2005, 101 consecutive rectal cancer patients who had been neoadjuvantly treated and had underne adjuvant CHT were retrospectively examined.
  • Forty-two patients had a lower (< or =5 cm from the anal verge), 54 a middle (from 6 to 10 cm) and 5 a higher (=10 cm) rectal lesion.
  • CONCLUSION: In our series, neither administration of oxaliplatin-based adjuvant chemotherapy (p=0.44) nor age > or =70 years (p=0.51), clinical stage III (p=0.67), tumour down-staging (p=0.44) and achievement of pCR (p=0.66) appeared to have a significant impact on TTP; only pN+ (patients "not responders" to a neoadjuvant CHT-RT) influenced local relapse requiring more accurate postoperative treatment and confirming the literature data about the utility of adjuvant therapy in stage III disease.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18630464.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


31. de Graeff P, Crijns AP, Ten Hoor KA, Klip HG, Hollema H, Oien K, Bartlett JM, Wisman GB, de Bock GH, de Vries EG, de Jong S, van der Zee AG: The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer; 2008 Jul 22;99(2):341-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer.
  • Ovarian cancer is the most frequent cause of death from gynaecological cancer in the Western world.
  • Current prognostic factors do not allow reliable prediction of response to chemotherapy and survival for individual ovarian cancer patients.
  • Epidermal growth factor receptor (EGFR) and HER-2/neu are frequently expressed in ovarian cancer but their prognostic value remains unclear.
  • In this study, we investigated the expression and prognostic value of EGFR, EGFR variant III (EGFRvIII), HER-2/neu and important downstream signalling components in a large series of epithelial ovarian cancer patients.
  • Our results show that negative PTEN immunostaining was associated with stage I/II disease (P=0.006), non-serous tumour type (P=0.042) and in multivariate analysis with a longer progression-free survival (P=0.015).
  • Negative PTEN staining also predicted improved progression-free survival in patients with grade III or undifferentiated serous carcinomas (P=0.011).
  • Positive pAKT staining was associated with advanced-stage disease (P=0.006).


32. Preoperative bi-fractionated accelerated radiation therapy for combined treatment of locally advanced rectal cancer in a consectutive series of unselected patients. Int Semin Surg Oncol; 2007 Sep 20;4:23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative bi-fractionated accelerated radiation therapy for combined treatment of locally advanced rectal cancer in a consectutive series of unselected patients.
  • METHODS: patients were screened following these eligibility criteria: histology-proven adenocarcinoma of the rectum; distal tumour extent at 12 cm or less from the anal verge; clinical stage T3-4/anyN, or anyT/N1-2; ECOG Performance Status 0-2.
  • Twenty-eight patients were stage II and 19 stage III.
  • CONCLUSION: bifractionated accelerated RT administered in the preoperative setting to patients bearing locally advanced rectal cancer is reliable and safe, as its immediate and late toxicity (mainly infectious) is acceptably low and long-term survivals are achievable.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1990 Feb;211(2):187-95 [2405793.001]
  • [Cites] Am J Surg. 1994 Jan;167(1):90-4; discussion 94-5 [8311145.001]
  • [Cites] Ann Surg. 1998 Feb;227(2):157-67 [9488510.001]
  • [Cites] J Natl Cancer Inst. 2000 Mar 1;92(5):388-96 [10699069.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Ann Surg. 2001 Nov;234(5):633-40 [11685026.001]
  • [Cites] Lancet. 2000 Jul 8;356(9224):93-6 [10963244.001]
  • [Cites] Ann Surg. 1994 Nov;220(5):676-82 [7979617.001]
  • [Cites] Br J Radiol. 1989 Aug;62(740):679-94 [2670032.001]
  • [Cites] Strahlenther Onkol. 2002 May;178(5):259-62 [12082685.001]
  • [Cites] Br J Surg. 1996 Jul;83(7):964-8 [8813788.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):67-73 [7826163.001]
  • [Cites] Dis Colon Rectum. 1992 Aug;35(8):757-61 [1643999.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 May;10(5):593-8 [6735750.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14):980-7 [9091798.001]
  • [Cites] N Engl J Med. 1994 Aug 25;331(8):502-7 [8041415.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2396 [10561302.001]
  • [Cites] Strahlenther Onkol. 2004 Jan;180(1):5-14 [14704839.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(2):387-92 [1587760.001]
  • [Cites] Lancet. 2001 Oct 20;358(9290):1291-304 [11684209.001]
  • [Cites] Clin Radiol. 1971 Apr;22(2):145-55 [5575251.001]
  • (PMID = 17883838.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2063497
  •  go-up   go-down


33. Garlipp B, Ptok H, Schmidt U, Meyer F, Gastinger I, Lippert H: Neoadjuvant chemoradiotherapy for rectal carcinoma: effects on anastomotic leak rate and postoperative bladder dysfunction after non-emergency sphincter-preserving anterior rectal resection. Results of the Quality Assurance in Rectal Cancer Surgery multicenter observational trial. Langenbecks Arch Surg; 2010 Nov;395(8):1031-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemoradiotherapy for rectal carcinoma: effects on anastomotic leak rate and postoperative bladder dysfunction after non-emergency sphincter-preserving anterior rectal resection. Results of the Quality Assurance in Rectal Cancer Surgery multicenter observational trial.
  • INTRODUCTION: Randomized trials have demonstrated a reduction in local recurrence rate in rectal cancer patients treated with preoperative chemoradiotherapy and total mesorectal excision (TME) compared to patients undergoing TME alone.
  • Accordingly, preoperative chemoradiotherapy in all UICC stages II and III rectal cancers has been recommended in the German treatment guidelines as of 2004.
  • It was the aim of our analysis to investigate the influence of preoperative chemoradiotherapy on anastomotic leak rate and postoperative bladder dysfunction in rectal cancer patients using a representative data set from the Quality Assurance in Rectal Cancer Surgery multicenter observational trial.
  • METHOD: This is a retrospective analysis of data from the Quality Assurance in Rectal Cancer Surgery prospective multicenter observational trial.
  • Data of all patients undergoing curatively intended sphincter-preserving resection for UICC stage I through III rectal carcinoma between 01 Jan 2005 and 31 Dec 2007 with or without preoperative chemoradiotherapy (groups A and B, respectively) were included.
  • Significant differences were present between groups regarding age, sex, distance of the tumor from the anal verge, pT-stage, UICC stage, hepatic risk factors, and use of protective enterostomy by univariate analysis.
  • CONCLUSION: Neoadjuvant chemoradiotherapy for rectal carcinoma does not increase the risk for anastomotic leakage or postoperative bladder dysfunction after curatively intended sphincter-preserving rectal resection.
  • [MeSH-major] Anal Canal / surgery. Anastomotic Leak / etiology. Neoadjuvant Therapy. Postoperative Complications / etiology. Quality Assurance, Health Care. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy. Rectum / surgery. Urinary Bladder Diseases / etiology

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Langenbecks Arch Surg. 2007 Mar;392(2):179-88 [17279430.001]
  • [Cites] Dis Colon Rectum. 2008 Aug;51(8):1195-201 [18523823.001]
  • [Cites] Zentralbl Chir. 2006 Aug;131(4):275-84 [17004186.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):129-36 [19304407.001]
  • [Cites] Int J Colorectal Dis. 2008 Mar;23(3):257-64 [18071720.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):49-55 [2191763.001]
  • [Cites] Z Gastroenterol. 2008 Aug;46(8):799-840 [18759205.001]
  • [Cites] Chirurg. 2009 Apr;80(4):303-10 [19350307.001]
  • [Cites] Ann Surg. 2005 Oct;242(4):502-10; discussion 510-1 [16192810.001]
  • [Cites] Int MS J. 2009 Sep;16(3):90-7 [19878631.001]
  • [Cites] Dis Colon Rectum. 2005 Oct;48(10):1868-74 [16175323.001]
  • [Cites] Br J Surg. 2006 Dec;93(12):1519-25 [17054311.001]
  • [Cites] JAMA. 2000 Aug 23-30;284(8):1008-15 [10944647.001]
  • [Cites] Br J Surg. 2001 Nov;88(11):1501-5 [11683749.001]
  • [Cites] Chirurg. 2009 Apr;80(4):266-73 [19271158.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):817-25 [11821466.001]
  • [Cites] Langenbecks Arch Surg. 2007 Sep;392(5):525-33 [17394012.001]
  • [Cites] Chirurg. 2003 May;74(5):444-50; discussion 450-1 [12748793.001]
  • [Cites] Surg Oncol. 2007 Dec;16 Suppl 1:S83-9 [18042378.001]
  • [Cites] Int J Colorectal Dis. 2003 Nov;18(6):495-9 [14517686.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] Ann Surg Oncol. 2007 May;14(5):1744-51 [17334851.001]
  • [Cites] J Gastrointest Surg. 2009 Mar;13(3):521-5 [19011946.001]
  • [Cites] Eur J Surg Oncol. 2006 Dec;32(10):1201-8 [16872799.001]
  • [Cites] Acta Oncol. 2003;42(5-6):476-92 [14596508.001]
  • [Cites] Dis Colon Rectum. 2002 Jul;45(7):934-9 [12130883.001]
  • [Cites] Colorectal Dis. 2007 Nov;9(9):801-7 [17931170.001]
  • [Cites] Dis Colon Rectum. 2003 May;46(5):621-8 [12792438.001]
  • [Cites] Am Surg. 2004 Dec;70(12):1045-9 [15663042.001]
  • [Cites] Cancer. 1996 Sep 1;78(5):968-76 [8780533.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):6199-206 [16135487.001]
  • [Cites] Ann Surg Oncol. 1996 Sep;3(5):423-30 [8876883.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):6126-31 [16135478.001]
  • [Cites] Colorectal Dis. 2004 Nov;6(6):462-9 [15521937.001]
  • [Cites] Zentralbl Chir. 2009 Jun;134(3):242-8 [19536719.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1311-20 [12654443.001]
  • [Cites] Eur J Surg. 1996 May;162(5):397-402 [8781922.001]
  • [Cites] Lancet. 2001 Oct 20;358(9290):1291-304 [11684209.001]
  • (PMID = 20711786.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


34. Endreseth BH, Myrvold HE, Romundstad P, Hestvik UE, Bjerkeset T, Wibe A, Norwegian Rectal Cancer Group: Transanal excision vs. major surgery for T1 rectal cancer. Dis Colon Rectum; 2005 Jul;48(7):1380-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transanal excision vs. major surgery for T1 rectal cancer.
  • PURPOSE: The purpose of this national study was to examine the long-term results of transanal excision compared with major surgery of T1 rectal cancer.
  • METHODS: This prospective study from the Norwegian Rectal Cancer Project included all 291 patients with a T1M0 tumor within 15 cm from the anal verge treated by anterior resection, abdominoperineal resection, Hartmann's procedure, or transanal excision in the period from November 1993 to December 1999.
  • There were no significant differences according to tumor localization, size, or differentiation between Stage I and Stage III tumors.
  • CONCLUSIONS: The main problem of transanal excision for early rectal cancer in the present study was the inability to remove all the malignancy.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Prognosis. Proportional Hazards Models. Prospective Studies. Statistics, Nonparametric. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15906120.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


35. Prete F, Prete FP, Nitti P, De Luca R, Vincenti L: [Evolution of surgery for cancer of the anorectal junction]. Chir Ital; 2007 Nov-Dec;59(6):763-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evolution of surgery for cancer of the anorectal junction].
  • [Transliterated title] Evoluzione chirurgica per i tumori del giunto ano-rettale.
  • Certain aspects of the epidemiology, classification and therapy of adenocarcinoma of the anorectal junction (< 5 cm from the anal verge) are not well standardised to date.
  • Intersphincteric resections were performed in 51 males and 33 females, mean age 62, with the following clinical stages: 28 stage 1, 55 stages II and III, 1 stage IV; radiotherapy was administered preoperatively to 27 patients and postoperatively to 18.
  • Assessment of anal sphincter function recovery one year after restoration of bowel continuity showed good continence in 76% of the patients; 2 patients have a permanent ostomy.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18360980.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


36. Taylor DD, Gercel-Taylor C, Parker LP: Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol Oncol; 2009 Oct;115(1):112-20
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer.
  • OBJECTIVE: Most ovarian cancers are diagnosed at advanced stage (67%) and prospects for significant improvement in survival reside in early diagnosis.
  • Our objective was to validate our array assay for the identification of ovarian cancer based on quantitation of tumor-reactive IgG.
  • Sera were obtained from age-matched female volunteers, women with benign ovarian disease and with ovarian cancer.
  • RESULTS: Sera from ovarian cancer patients exhibited significantly greater immunoreactivities than either normal controls or women with benign disease (both considered negative to all antigens tested).
  • Reactivities with nucleophosmin, cathepsin D, p53, and SSX common antigen for patients with all stages of ovarian cancer were significantly higher than for controls and women with benign ovarian disease.
  • Reactivity with placental type alkaline phosphatase, TAG 72, survivin, NY-ESO-1, GRP78, and Muc16 (CA125) allowed the differentiation between Stage III/IV and early stage ovarian cancer.
  • CONCLUSIONS: The quantitation of circulating tumor-reactive IgG can be used to identify the presence of ovarian cancer.
  • The analyses of IgG recognition of specific exosomal antigens allows for the differentiation of women with benign ovarian masses from ovarian cancer, as well as distinguishing early and late stage ovarian cancers.
  • Thus, the quantitative assessment of IgG reactive with specific tumor-derived exosomal proteins can be used as diagnostic markers for ovarian cancer.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1993 Oct 21;55(4):678-84 [8406999.001]
  • [Cites] Cancer. 1993 Jan 1;71(1):26-35 [8380118.001]
  • [Cites] J Cell Biochem Suppl. 1995;23:189-99 [8747396.001]
  • [Cites] J Soc Gynecol Investig. 1996 Jul-Aug;3(4):216-22 [8796833.001]
  • [Cites] Gynecol Oncol. 1997 Apr;65(1):13-22 [9103385.001]
  • [Cites] Cancer Lett. 1997 Jun 3;116(1):93-101 [9177463.001]
  • [Cites] J Exp Med. 1998 Apr 20;187(8):1163-7 [9547328.001]
  • [Cites] Oncol Rep. 1998 Nov-Dec;5(6):1519-24 [9769398.001]
  • [Cites] J Proteome Res. 2005 Jul-Aug;4(4):1123-33 [16083262.001]
  • [Cites] Expert Rev Mol Diagn. 2005 Sep;5(5):735-43 [16149876.001]
  • [Cites] N Engl J Med. 2005 Sep 22;353(12):1288-90 [16177255.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81 [16343244.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1181-90 [16424057.001]
  • [Cites] Biochim Biophys Acta. 2006 Apr;1762(4):398-403 [16483750.001]
  • [Cites] PLoS One. 2007;2(12):e1281 [18060075.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):764-71 [18245537.001]
  • [Cites] Adv Exp Med Biol. 2008;622:15-21 [18546615.001]
  • [Cites] PLoS Med. 2008 Aug 19;5(8):e170 [18715113.001]
  • [Cites] Am J Obstet Gynecol. 2008 Sep;199(3):215-23 [18468571.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2009 Feb;142(2):99-105 [18995946.001]
  • [Cites] Methods Mol Biol. 2009;520:21-38 [19381945.001]
  • [Cites] Clin Biochem. 2000 Feb;33(1):53-62 [10693987.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;46 Suppl:S3-7 [10950139.001]
  • [Cites] Br J Cancer. 2000 Nov;83(10):1338-43 [11044359.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4060-5 [11274429.001]
  • [Cites] Gynecol Oncol. 2001 Apr;81(1):71-6 [11277653.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):138-43 [11330940.001]
  • [Cites] Cancer Detect Prev. 2001;25(2):117-22 [11341346.001]
  • [Cites] Int J Oncol. 2001 Aug;19(2):387-94 [11445857.001]
  • [Cites] J Reprod Med. 2001 Jul;46(7):621-9; discussion 629-30 [11499181.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7908-12 [11691811.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14571-6 [11724951.001]
  • [Cites] Int J Cancer. 2001 Dec 15;94(6):859-63 [11745489.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):168s-174s [12743131.001]
  • [Cites] Clin Biochem. 2004 Jul;37(7):512-8 [15234232.001]
  • [Cites] Int J Cancer. 2004 Sep 20;111(5):720-6 [15252841.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Anal Biochem. 1979 Sep 15;98(1):53-9 [396817.001]
  • [Cites] Am J Reprod Immunol. 1984 Dec;6(4):179-84 [6528883.001]
  • [Cites] Cancer Res. 1989 Mar 15;49(6):1361-5 [2924293.001]
  • [Cites] Am J Pathol. 1992 Apr;140(4):859-70 [1314027.001]
  • [Cites] Lancet. 1995 Jan 14;345(8942):126 [7815863.001]
  • (PMID = 19647308.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA098166-02; United States / NCI NIH HHS / CA / R21 CA098166-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / Epitopes; 0 / Immunoglobulin G
  • [Other-IDs] NLM/ NIHMS129188; NLM/ PMC2760307
  •  go-up   go-down


37. Weiser MR, Quah HM, Shia J, Guillem JG, Paty PB, Temple LK, Goodman KA, Minsky BD, Wong WD: Sphincter preservation in low rectal cancer is facilitated by preoperative chemoradiation and intersphincteric dissection. Ann Surg; 2009 Feb;249(2):236-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sphincter preservation in low rectal cancer is facilitated by preoperative chemoradiation and intersphincteric dissection.
  • OBJECTIVE: The aim of this study was to evaluate oncologic outcome in patients with locally advanced distal rectal cancer treated with preoperative chemoradiation followed by low anterior resection (LAR)/stapled coloanal anastomosis, LAR/intersphincteric dissection/hand-sewn coloanal anastomosis, or abdominoperineal resection (APR).
  • SUMMARY BACKGROUND DATA: Distal rectal cancer presents a surgical challenge, and the goals of treatment often include tumor eradication without sacrifice of the anal sphincters.
  • The technique of intersphincteric resection removes the internal anal sphincter to gain additional distal rectal margin in hopes of avoiding a permanent stoma.
  • METHODS: We analyzed 148 patients with stage II and III rectal cancers (endorectal ultrasound staged uT3-4 and/or uN1) located < or =6 cm from the anal verge, treated by preoperative chemoradiation and total mesorectal excision from 1998 to 2004.
  • CONCLUSIONS: In low rectal cancer, sphincter preservation is facilitated by a significant response to preoperative chemoradiation and intersphincteric resection, without compromise of margins or outcome.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / physiopathology. Anal Canal / surgery. Antineoplastic Agents / administration & dosage. Colectomy. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212176.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


38. Serra-Aracil X, Vallverdú H, Bombardó-Junca J, Pericay-Pijaume C, Urgellés-Bosch J, Navarro-Soto S: Long-term follow-up of local rectal cancer surgery by transanal endoscopic microsurgery. World J Surg; 2008 Jun;32(6):1162-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of local rectal cancer surgery by transanal endoscopic microsurgery.
  • BACKGROUND: In 1997 we launched a prospective program of transanal endoscopic microsurgery (TEM) for the treatment of rectal cancer.
  • (III) adenocarcinomas uT2- uN0, low histological grade with intention to cure; and (IV) advanced stage adenocarcinomas with palliative care RESULTS: Transanal endoscopic microsurgery was performed in 218 patients: 122 adenomas, and 96 adenocarcinomas: group II-72, group III-19, and group IV-5.
  • Nine were lost to follow-up, and so 52 patients were studied: group II-38, group III-11, and group IV-3.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Female. Follow-Up Studies. Humans. Male. Microsurgery. Middle Aged. Prospective Studies. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):429-37 [15747069.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1182-92 [15793641.001]
  • [Cites] Am J Surg. 2000 Dec;180(6):402-5; discussion 405-6 [11182387.001]
  • [Cites] Hepatogastroenterology. 2005 Mar-Apr;52(62):460-3 [15816457.001]
  • [Cites] Dis Colon Rectum. 1983 Mar;26(3):149-51 [6825519.001]
  • [Cites] Dis Colon Rectum. 1995 Dec;38(12):1286-95 [7497841.001]
  • [Cites] Surg Laparosc Endosc. 1998 Aug;8(4):249-56 [9703594.001]
  • [Cites] Surg Endosc. 2003 Aug;17(8):1283-7 [12739119.001]
  • [Cites] Dis Colon Rectum. 1993 Jan;36(1):77-97 [8416784.001]
  • [Cites] Gut. 1977 Dec;18(12):1045-50 [606631.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):260-8 [15273550.001]
  • [Cites] Lancet. 1986 Jun 28;1(8496):1479-82 [2425199.001]
  • [Cites] Am J Surg. 1998 May;175(5):360-3 [9600277.001]
  • [Cites] Dis Colon Rectum. 2005 Apr;48(4):711-9; discussion 719-21 [15768186.001]
  • [Cites] Dis Colon Rectum. 1984 Feb;27(2):81-3 [6697834.001]
  • [Cites] Dis Colon Rectum. 1997 Apr;40(4):388-92 [9106685.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]
  • [Cites] Colorectal Dis. 2001 Mar;3(2):122-5 [12791005.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):522-29; discussion 529-30 [12368681.001]
  • [Cites] Dis Colon Rectum. 2000 Aug;43(8):1064-71; discussion 1071-4 [10950004.001]
  • [Cites] World J Surg. 2002 Sep;26(9):1170-4 [12209248.001]
  • [Cites] Colorectal Dis. 2004 Nov;6(6):432-7 [15521931.001]
  • [Cites] Ann Surg. 2000 Mar;231(3):345-51 [10714627.001]
  • [Cites] Ann Surg Oncol. 1999 Jul-Aug;6(5):433-41 [10458680.001]
  • [Cites] Dis Colon Rectum. 1994 Jan;37(1):52-7 [8287748.001]
  • [Cites] Am J Surg. 1992 Jan;163(1):63-9; discussion 69-70 [1733375.001]
  • (PMID = 18338206.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Natarajan L, Pu M, Parker BA, Thomson CA, Caan BJ, Flatt SW, Madlensky L, Hajek RA, Al-Delaimy WK, Saquib N, Gold EB, Pierce JP: Time-varying effects of prognostic factors associated with disease-free survival in breast cancer. Am J Epidemiol; 2009 Jun 15;169(12):1463-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time-varying effects of prognostic factors associated with disease-free survival in breast cancer.
  • Early detection and effective treatments have dramatically improved breast cancer survivorship, yet the risk of relapse persists even 15 years after the initial diagnosis.
  • It is important to identify prognostic factors for late breast cancer events.
  • The authors investigated time-varying effects of tumor characteristics on breast-cancer-free survival using data on 3,088 breast cancer survivors from 4 US states who participated in a randomized dietary intervention trial in 1995-2006, with maximum follow-up through 15 years (median, 9 years).
  • Having a stage II or III tumor was associated with a 3-fold higher hazard of breast cancer than having a stage I tumor during the first 2.5 years after diagnosis; this hazard ratio decreased to 2.1 after 7.7 years, but higher tumor stage remained a significant risk factor.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Radiat Oncol. 2002 Oct;12(4):319-28 [12382190.001]
  • [Cites] JAMA. 2007 Jul 18;298(3):289-98 [17635889.001]
  • [Cites] Breast Cancer Res Treat. 2003 Mar;78(1):105-18 [12611463.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1331-6 [15042664.001]
  • [Cites] Biometrics. 2004 Jun;60(2):344-51 [15180659.001]
  • [Cites] Biometrics. 1989 Mar;45(1):135-44 [2720049.001]
  • [Cites] Lifetime Data Anal. 1997;3(1):13-25 [9384623.001]
  • [Cites] Breast Cancer Res Treat. 1998;52(1-3):227-37 [10066085.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1687-717 [15894097.001]
  • [Cites] JAMA. 2006 Apr 12;295(14):1658-67 [16609087.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2492-502 [16757721.001]
  • [Cites] Stat Med. 2006 Aug 30;25(16):2831-45 [16158396.001]
  • [Cites] Biom J. 2007 Jun;49(3):453-73 [17623349.001]
  • [Cites] Clin Cancer Res. 2008 Jul 1;14(13):4168-74 [18593996.001]
  • [Cites] J Natl Cancer Inst. 2008 Aug 20;100(16):1179-83 [18695137.001]
  • [Cites] Breast Cancer Res Treat. 2009 Aug;116(3):595-602 [18830816.001]
  • [Cites] Control Clin Trials. 2002 Dec;23(6):728-56 [12505249.001]
  • (PMID = 19403844.001).
  • [ISSN] 1476-6256
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA069375-09; United States / NCI NIH HHS / CA / R01 CA069375-06S1; United States / NCRR NIH HHS / RR / M01 RR000079; United States / NCI NIH HHS / CA / R01 CA069375-04S3; United States / NCI NIH HHS / CA / R01 CA069375-04S4; United States / NCI NIH HHS / CA / R01 CA069375-05S5; United States / NCRR NIH HHS / RR / M01-RR00827; United States / NCI NIH HHS / CA / R01 CA069375-06S2; United States / NCI NIH HHS / CA / R01 CA069375-05S1; United States / NCI NIH HHS / CA / R01 CA069375-03S1; United States / NCI NIH HHS / CA / CA 69375; United States / NCI NIH HHS / CA / R01 CA069375-04S2; United States / NCI NIH HHS / CA / R01 CA069375-08; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NCI NIH HHS / CA / R01 CA069375-04; United States / NCI NIH HHS / CA / R01 CA069375-05; United States / NCI NIH HHS / CA / R01 CA069375-02; United States / NCI NIH HHS / CA / CA069375-08; United States / NCRR NIH HHS / RR / M01-RR00070; United States / NCI NIH HHS / CA / R01 CA069375-06; United States / NCI NIH HHS / CA / R01 CA069375-10; United States / NCI NIH HHS / CA / R01 CA069375-05S4; United States / NCI NIH HHS / CA / R01 CA069375-03; United States / NCI NIH HHS / CA / R01 CA069375-07; United States / NCI NIH HHS / CA / R01 CA069375-05S2; United States / NCRR NIH HHS / RR / M01 RR000070; United States / NCI NIH HHS / CA / R01 CA069375-04S1; United States / NCRR NIH HHS / RR / M01 RR000827; United States / NCI NIH HHS / CA / R01 CA069375-02S1; United States / NCI NIH HHS / CA / R01 CA069375; United States / NCI NIH HHS / CA / R01 CA069375-05S3
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2733768
  •  go-up   go-down


40. Chung FY, Huang MY, Yeh CS, Chang HJ, Cheng TL, Yen LC, Wang JY, Lin SR: GLUT1 gene is a potential hypoxic marker in colorectal cancer patients. BMC Cancer; 2009;9:241
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GLUT1 gene is a potential hypoxic marker in colorectal cancer patients.
  • This study investigated molecules synthesized in colorectal cancer cells during hypoxia to explore the possibility of developing molecular probes capable of detecting cell death and/or the efficiency of radiotherapy and chemotherapy.
  • METHODS: At first, we incubated two human colorectal adenocarcinoma cell lines SW480 (UICC stage II) and SW620 (UICC stage III) cells in hypoxic (< or =2% O2, 93% N2, and 5% CO2) and normoxic conditions (20% O2, 75% N2, and 5% CO2) for 24 h and 48 h.
  • Ten cancerous tissues collected from human colorectal cancer patients were examined.
  • The elevated ratio of GLUT1 was higher in stage III and IV CRC tissue specimens than in the stage I and II (2.97-4.73 versus 1.44-2.11).
  • GLUT1 mRNA was also increased in the peripheral blood of stage II and III CRC patients as compared to stage I patients, suggesting that GLUT1 may serve as a hypoxic indicator in CRC patients.
  • CONCLUSION: In conclusion, this study demonstrated that GLUT1 has the potential to be employed as a molecular marker to indicate the degree of hypoxia experienced by tumors circulating in the blood of cancer patients.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Abdom Imaging. 2008 May-Jun;33(3):270-7 [17610107.001]
  • [Cites] Eur J Cancer. 2008 Mar;44(5):692-8 [18314327.001]
  • [Cites] Mol Cell Endocrinol. 2008 Sep 10;291(1-2):57-62 [18571834.001]
  • [Cites] Colorectal Dis. 2009 Mar;11(3):276-81 [18513194.001]
  • [Cites] CA Cancer J Clin. 2002 Nov-Dec;52(6):326-41 [12469762.001]
  • [Cites] Hepatogastroenterology. 2000 Jan-Feb;47(31):57-70 [10690586.001]
  • [Cites] J Exp Biol. 2000 Apr;203(Pt 8):1253-63 [10729275.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] Cancer Lett. 2000 Jun 30;154(2):175-82 [10806305.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4693-6 [10987269.001]
  • [Cites] Prev Med. 2000 Oct;31(4):410-6 [11006067.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14608-13 [11121063.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] Urology. 2002 Oct;60(4):634-9 [12385924.001]
  • [Cites] Eur J Surg Oncol. 2004 Jun;30(5):465-8 [15135470.001]
  • [Cites] J Natl Cancer Inst. 1967 Jun;38(6):839-63 [4381692.001]
  • [Cites] Cancer Res. 1972 Oct;32(10):2007-16 [4343003.001]
  • [Cites] Prog Exp Tumor Res. 1978;22:190-274 [149996.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Aug;83(16):5784-8 [3016720.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Diabetes. 1988 May;37(5):657-61 [2834252.001]
  • [Cites] J Biol Chem. 1989 Nov 15;264(32):18884-9 [2553725.001]
  • [Cites] J Biol Chem. 1992 Jul 25;267(21):14523-6 [1634504.001]
  • [Cites] Radiother Oncol. 1993 Jan;26(1):45-50 [8438086.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):401-9 [7688183.001]
  • [Cites] Eur J Surg Oncol. 1995 Jun;21(3):269-75 [7781795.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):941-3 [8640781.001]
  • [Cites] Stem Cells. 1996 Jan;14(1):10-5 [8820945.001]
  • [Cites] NMR Biomed. 1996 Aug;9(5):185-94 [9067999.001]
  • [Cites] Gastroenterology. 1997 Apr;112(4):1103-13 [9097992.001]
  • [Cites] Genes Dev. 1998 Jan 15;12(2):149-62 [9436976.001]
  • [Cites] Trends Biochem Sci. 1999 Feb;24(2):68-72 [10098401.001]
  • [Cites] Oncologia. 1956;9(2):75-83 [13335077.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8554-60 [15623639.001]
  • [Cites] DNA Cell Biol. 2005 Feb;24(2):126-32 [15699632.001]
  • [Cites] Cancer Lett. 2005 Nov 8;229(1):115-22 [16157223.001]
  • [Cites] Int J Oncol. 2006 Feb;28(2):411-20 [16391796.001]
  • [Cites] Cytometry B Clin Cytom. 2006 Mar;70(2):45-55 [16456867.001]
  • [Cites] Int J Mol Med. 2006 May;17(5):737-47 [16596255.001]
  • [Cites] Cancer Lett. 2006 Aug 28;240(2):279-88 [16289546.001]
  • [Cites] Int J Radiat Biol. 2006 Oct;82(10):699-757 [17118889.001]
  • [Cites] Strahlenther Onkol. 2007 May;183(5):265-70 [17497098.001]
  • [Cites] Antioxid Redox Signal. 2007 Aug;9(8):1221-35 [17536958.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):167-75 [17707270.001]
  • [Cites] J Natl Cancer Inst. 2007 Oct 3;99(19):1441-54 [17895480.001]
  • [Cites] Jpn J Clin Oncol. 2007 Dec;37(12):955-60 [18211986.001]
  • [Cites] Ann Oncol. 2008 Feb;19(2):348-52 [17962202.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2007 Sep;29(9):697-700 [18246802.001]
  • [Cites] Adv Exp Med Biol. 2008;614:127-36 [18290322.001]
  • [Cites] Gynecol Oncol. 2008 Mar;108(3):603-8 [18191183.001]
  • [Cites] BMC Cancer. 2008;8:194 [18616803.001]
  • (PMID = 19619276.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ARNT protein, human; 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / RNA, Messenger; 138391-32-9 / Aryl Hydrocarbon Receptor Nuclear Translocator
  • [Other-IDs] NLM/ PMC3087329
  •  go-up   go-down


41. Zhang L, Chen J, Ke Y, Mansel RE, Jiang WG: Expression of Placenta growth factor (PlGF) in non-small cell lung cancer (NSCLC) and the clinical and prognostic significance. World J Surg Oncol; 2005 Oct 13;3:68

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Placenta growth factor (PlGF) in non-small cell lung cancer (NSCLC) and the clinical and prognostic significance.
  • This study examined PlGF expression at protein and message levels in non-small cell lung cancer (NSCLC), in which no reports on the significance of PlGF expression is available to date.
  • RESULTS: PlGF was positively stained mainly in cytoplasm of lung cancer cells.
  • Real time PCR analysis revealed that PlGF mRNA was higher in the cancer tissue than normal tissue (0.95 +/- 0.19 vs. 0.57 +/- 0.24; p < 0.005) and that PlGF mRNA was significant higher in III-IV stage patients than in I-II stage patients (1.03 +/- 0.20 vs. 0.80 +/- 0.17; p = 0.011).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 1999 Jan;14(1):161-8 [9863024.001]
  • [Cites] J Biol Chem. 1994 Oct 14;269(41):25646-54 [7929268.001]
  • [Cites] J Biol Chem. 1995 Mar 31;270(13):7717-23 [7706320.001]
  • [Cites] Oncogene. 1993 Apr;8(4):925-31 [7681160.001]
  • [Cites] Nature. 1995 Jul 6;376(6535):66-70 [7596436.001]
  • [Cites] Nature. 1995 Jul 6;376(6535):62-6 [7596435.001]
  • [Cites] Eur J Cancer. 2005 Jul;41(11):1628-36 [15951164.001]
  • [Cites] Tumour Biol. 2004 Jan-Apr;25(1-2):1-6 [15192305.001]
  • [Cites] J Clin Pathol. 2004 Jun;57(6):591-7 [15166262.001]
  • [Cites] Adv Cancer Res. 1995;67:281-316 [8571818.001]
  • [Cites] J Biol Chem. 1996 Feb 9;271(6):3154-62 [8621715.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2671-6 [8653715.001]
  • [Cites] Anal Biochem. 1997 Feb 15;245(2):154-60 [9056205.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Jun 27;235(3):493-8 [9207183.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1803-4 [9351551.001]
  • [Cites] Hum Pathol. 2002 Nov;33(11):1069-77 [12454810.001]
  • [Cites] J Biol Chem. 1992 Jun 5;267(16):10931-4 [1375931.001]
  • [Cites] J Clin Pathol. 1998 Oct;51(10):771-5 [10023341.001]
  • [Cites] Nat Med. 2001 May;7(5):575-83 [11329059.001]
  • (PMID = 16223445.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1276823
  •  go-up   go-down


42. Vini L: Neoadjuvant radiochemotherapy for rectal cancer. Dig Dis; 2007;25(1):56-66
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant radiochemotherapy for rectal cancer.
  • During the past few decades, significant progress has been achieved in the management of rectal cancer with the introduction of total mesorectal excision.
  • Several recent studies show that 5-FU-based chemotherapy enhances tumor response to radiotherapy and preoperative chemoradiotherapy is being increasingly used for stage II and III disease.
  • [MeSH-minor] Anal Canal. Combined Modality Therapy. Humans. Preoperative Care. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 S. Karger AG, Basel.
  • (PMID = 17384509.001).
  • [ISSN] 0257-2753
  • [Journal-full-title] Digestive diseases (Basel, Switzerland)
  • [ISO-abbreviation] Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


43. Suzuki A, Kawamoto S, Inada K, Yamamoto N, Kojima T, Nagao S, Ochiai R: [A resected case of bleeding rectal cancer for Jehovah's Witness enabled with preceding colostomy and chemoradiation]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2079-81
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A resected case of bleeding rectal cancer for Jehovah's Witness enabled with preceding colostomy and chemoradiation].
  • A 66-year-old woman, complaining of anal bleeding with anemia, was examined and diagnosed as advanced rectal cancer.
  • Pathological findings showed moderately differentiated adenocarcinoma with Stage III a.
  • The patient has survived for 31 months with no recurrence, which indicates that preceded colostomy and preoperative chemoradiation enabled a curative resection safely for the Jehovah's Witness patient with bleeding advanced rectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037329.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


44. Gervaz P, Lavertu S, Kazemba B, Pemberton JH, Haddock MG, Gunderson LL: Sphincter-preserving radiation therapy for rectal cancer: a simulation study using three-dimensional computerized technology. Colorectal Dis; 2006 Sep;8(7):570-4
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sphincter-preserving radiation therapy for rectal cancer: a simulation study using three-dimensional computerized technology.
  • This approach provides, in theory, a means to selectively subtract the anal sphincter from the high-dose field of irradiation in patients with stage II and III adenocarcinomas of the mid-rectum scheduled for low anterior resection (LAR).
  • HYPOTHESIS: Implementation of 3DXRT with sphincter blocking may be a feasible strategy to reduce the dose of radiation distributed to the anal canal without reduction in the dose distribution to the gross tumour volume (GTV) plus adequate margins.
  • METHODS: Pretreatment simulation CT scans of 10 patients with rectal cancers located between 5 and 10 cm from the anal verge were retrieved from a computerized database.
  • Radiation oncologists and colorectal surgeons defined the contours of the GTV and the anal sphincter, respectively, on successive CT scan slices.
  • RESULTS: The mean distance of tumours from the anal verge was 6.3 cm.
  • The mean volume of the anal sphincter was 16.1 +/- 3.5 cm(3).
  • By comparison the mean dose distributed to the anal sphincter was dramatically reduced by using a sphincter block (33.2 +/- 12 Gy vs 6.4 +/- 4.1 Gy, P < 0.001).
  • CONCLUSION: During a course of radiotherapy for most low- or mid-rectal cancers, the anal canal is included within the field of irradiation with a mean dose distribution to the sphincter of 33 Gy.
  • Evaluation of 3DXRT with full sphincter block (mid-rectum) and partial sphincter block (distal rectum) is a feasible strategy to decrease the volume of anal sphincter carried to full dose without reduction in dose to the GTV.
  • This approach, by minimizing treatment-induced damage to the anal sphincter, might improve functional outcome of LAR.
  • [MeSH-major] Anal Canal / radiation effects. Computer Simulation. Radiotherapy Planning, Computer-Assisted. Rectal Neoplasms / radiotherapy. Rectal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16919108.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


45. O'Neil BH, Tepper JE: Current options for the management of rectal cancer. Curr Treat Options Oncol; 2007 Oct;8(5):331-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current options for the management of rectal cancer.
  • Patients diagnosed with rectal cancer should undergo locoregional staging with transrectal endoscopic ultrasound (EUS) or surface coil array MRI of the pelvis if that technique is available.
  • Patients thought to have more than very early stage (T1 or T2) disease should undergo abdominal imaging as well by CT or MRI, and chest imaging with either CXR or preferably CT.
  • The care of rectal cancer patients should be coordinated amongst an experienced multidisciplinary team to maximize the chance of cure and to minimize both local recurrence and complications of therapy.
  • For patients with very early stage disease (T1N0 or T2N0), local resection with or without chemoradiation may be adequate therapy, but these patients must be selected carefully and should be without any poor prognostic factors.
  • For the majority of patients with T3N0 or greater rectal cancer, standard therapy consists of neoadjuvant continuous 5-FU and radiation followed by surgery and further chemotherapy (either with 5-FU, capecitabine, or FOLFOX).
  • The use of capecitabine, irinotecan, and oxaliplatin during radiotherapy shows promise, but remains investigational pending results of phase III studies.
  • Select patients with high (>10 cm from the anal verge) uT3N0 tumors may be at sufficiently low risk of local recurrence to justify omission of radiotherapy.
  • Patients with stage IV rectal cancer may still require local therapy with radiation, surgery, or both; however, care should be taken in these patients that chemotherapy is not excessively delayed as this is the one modality in this case that can result in improved survival.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Sep;12(9):1559-63 [3759580.001]
  • [Cites] Ann Surg. 2002 Nov;236(5):583-92 [12409664.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14 ):980-7 [9091798.001]
  • [Cites] Ann Oncol. 2007 Apr;18(4):738-44 [17208931.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] N Engl J Med. 2006 Sep 14;355(11):1114-23 [16971718.001]
  • [Cites] Cancer. 1992 Jan 15;69(2):335-41 [1728364.001]
  • [Cites] Eur J Surg Oncol. 1986 Dec;12(4):373-7 [3780991.001]
  • [Cites] Eur J Cancer. 1994;30A(8):1092-5 [7654436.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3623-8 [14512393.001]
  • [Cites] Br J Surg. 2007 Feb;94(2):129-31 [17256808.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1155-60 [16035135.001]
  • [Cites] Oncology (Williston Park). 1989 May;3(5):137-42; discussion 142, 146-8 [2577881.001]
  • [Cites] Clin Radiol. 2006 Nov;61(11):916-23 [17018303.001]
  • [Cites] Oncology (Williston Park). 2006 Apr;20(5):461-9; discussion 469-70, 473-5 [16739745.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9243-9 [16230673.001]
  • [Cites] Cancer. 1989 Apr 1;63(7):1421-9 [2920368.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):386-96 [12243812.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):912-7 [17325705.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):166-74 [14701779.001]
  • [Cites] Br J Cancer. 1984 Oct;50(4):435-42 [6487514.001]
  • [Cites] Ann Oncol. 2007 Jul;18 Suppl 9:ix122-6 [17631564.001]
  • [Cites] Lancet. 1986 Jun 28;1(8496):1479-82 [2425199.001]
  • [Cites] Br J Cancer. 2006 Sep 18;95(6):710-6 [16940980.001]
  • [Cites] N Engl J Med. 1991 Mar 14;324(11):709-15 [1997835.001]
  • [Cites] Semin Radiat Oncol. 2003 Oct;13(4):389-402 [14586829.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8697-705 [16314629.001]
  • [Cites] Arch Surg. 1991 Jun;126(6):696-701; discussion 701-2 [2039356.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2557-62 [16636336.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):549-57 [1548520.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):650-5 [16446336.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):762-71 [17011451.001]
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):651-7 [10560850.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] Ann Oncol. 2006 Feb;17(2):246-51 [16282246.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Nov 15;27(4):779-83 [8244805.001]
  • [Cites] Semin Radiat Oncol. 2003 Oct;13(4):469-77 [14586835.001]
  • [Cites] Dis Colon Rectum. 2005 Jul;48(7):1353-65 [15868235.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):668-74 [16446339.001]
  • [Cites] N Engl J Med. 1994 Aug 25;331(8):502-7 [8041415.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1785-96 [15067027.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):201-5 [16814947.001]
  • [Cites] N Engl J Med. 1985 Jun 6;312(23 ):1465-72 [2859523.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]
  • [Cites] Ann Surg. 2007 May;245(5):726-33 [17457165.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):110-7 [17194912.001]
  • [Cites] Am J Surg. 1992 Jan;163(1):63-9; discussion 69-70 [1733375.001]
  • (PMID = 18181024.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5 K23 CA 118431-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  • [Number-of-references] 51
  •  go-up   go-down


46. Deschoolmeester V, Baay M, Wuyts W, Van Marck E, Pelckmans P, Lardon F, Vermorken JB: Comparison of three commonly used PCR-based techniques to analyze MSI status in sporadic colorectal cancer. J Clin Lab Anal; 2006;20(2):52-61
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of three commonly used PCR-based techniques to analyze MSI status in sporadic colorectal cancer.
  • Several retrospective studies have shown that a high level of microsatellite instability (MSI-H) is an important prognostic factor of a more favorable outcome in stage II and III colorectal cancer (CRC) patients.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16538640.001).
  • [ISSN] 0887-8013
  • [Journal-full-title] Journal of clinical laboratory analysis
  • [ISO-abbreviation] J. Clin. Lab. Anal.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


47. Zou YP, Li WM, Zheng F, Li FC, Huang H, Du JD, Liu HR: Intraoperative radiofrequency ablation combined with 125 iodine seed implantation for unresectable pancreatic cancer. World J Gastroenterol; 2010 Oct 28;16(40):5104-10
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative radiofrequency ablation combined with 125 iodine seed implantation for unresectable pancreatic cancer.
  • AIM: To evaluate the feasibility, efficacy and safety of intraoperative radiofrequency ablation (RFA) combined with (125)iodine seed implantation for unresectable pancreatic cancer.
  • METHODS: Thirty-two patients (21 males and 11 females) at the age of 68 years (range 48-90 years) with unresectable locally advanced pancreatic cancer admitted to our hospital from January 2006 to May 2008 were enrolled in this study.
  • Diagnosis of pancreatic cancer was made through intraoperative biopsy.
  • The median survival time of patients at stage III was longer than that of those at stage IV (19 mo vs 10 mo, P = 0.0026).
  • CONCLUSION: Intraoperative RFA combined with (125)iodine seed implantation is a feasible and safe procedure for unresectable pancreatic cancer with acceptable minor complications, and can prolong the survival time of patients, especially those at stage III.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2003 Feb 1;97(3):554-60 [12548596.001]
  • [Cites] Breast Cancer. 2003;10(1):4-9 [12525756.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1346-52 [12599244.001]
  • [Cites] Eur J Surg Oncol. 2004 Feb;30(1):85-7 [14736529.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Pancreas. 2004 Apr;28(3):219-30 [15084961.001]
  • [Cites] Lancet. 1974 Nov 9;2(7889):1127-31 [4139420.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Nov;17(5):931-5 [2808054.001]
  • [Cites] Ann Surg. 1990 Aug;212(2):132-9 [1695834.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(2):305-11 [1587751.001]
  • [Cites] Lifetime Data Anal. 1999;5(1):81-90 [10214004.001]
  • [Cites] Gastrointest Endosc. 1999 Sep;50(3):392-401 [10462663.001]
  • [Cites] Minim Invasive Neurosurg. 2004 Dec;47(6):325-8 [15674746.001]
  • [Cites] Clin Liver Dis. 2005 May;9(2):301-14, viii [15831275.001]
  • [Cites] Hepatogastroenterology. 2005 Jul-Aug;52(64):1281-92 [16001679.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1345-50 [16029791.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Aug;5(4):657-66 [16111466.001]
  • [Cites] Invest Radiol. 2005 Sep;40(9):583-90 [16118551.001]
  • [Cites] Prostate. 2005 Nov 1;65(3):260-7 [16015591.001]
  • [Cites] Eur J Radiol. 2005 Dec;56(3):403-8 [15964164.001]
  • [Cites] JOP. 2006;7(1):1-4 [16407612.001]
  • [Cites] JOP. 2006;7(1):74-8 [16407624.001]
  • [Cites] J Surg Oncol. 2006 May 1;93(6):485-90 [16615151.001]
  • [Cites] Langenbecks Arch Surg. 2007 Jan;392(1):55-60 [17089173.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] Semin Oncol. 2007 Aug;34(4):327-34 [17674961.001]
  • [Cites] Ann Oncol. 2008 Jul;19(7):1224-30 [18381371.001]
  • [Cites] J Clin Oncol. 2009 Nov 20;27(33):5513-8 [19858379.001]
  • [Cites] Pancreas. 2000 Jan;20(1):14-20 [10630378.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Arch Surg. 2000 Mar;135(3):332-5 [10722037.001]
  • [Cites] Acta Chir Iugosl. 2002;49(3):19-24 [12587443.001]
  • (PMID = 20976848.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  • [Other-IDs] NLM/ PMC2965288
  •  go-up   go-down


48. Velenik V, Anderluh F, Oblak I, Strojan P, Zakotnik B: Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial. Croat Med J; 2006 Oct;47(5):693-700
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
  • AIM: To evaluate the efficacy and toxicity of preoperative chemoradiotherapy with capecitabine in locally advanced rectal cancer.
  • METHODS: Between June 2004 and January 2005, 57 patients with operable, clinical stage II-III adenocarcinoma of the rectum entered the prospective phase II study.
  • Total sphincter preservation rate was 65.5% (36 out of 55 patients) and the rate in 27 patients with tumors located within 5 cm of the anal opening was 37% (10 out of 27 patients).

  • Genetic Alliance. consumer health - Rectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 2000;45(4):291-7 [10755317.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):346-53 [15913913.001]
  • [Cites] Bioorg Med Chem. 2000 Jul;8(7):1697-706 [10976516.001]
  • [Cites] Eur J Cancer. 2001 Mar;37(5):597-604 [11290435.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):675-9 [12062611.001]
  • [Cites] Lancet Oncol. 2002 Jul;3(7):415-24 [12142171.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):403-8 [12243814.001]
  • [Cites] Clin Ther. 2004 Apr;26(4):579-89 [15189755.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):110-5 [8996131.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14):980-7 [9091798.001]
  • [Cites] Dis Colon Rectum. 1997 Feb;40(2):131-9 [9075745.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5 Suppl 18):S18-8-S18-18 [9420016.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):301-8 [9440757.001]
  • [Cites] Dis Colon Rectum. 1998 May;41(5):543-9; discussion 549-51 [9593234.001]
  • [Cites] Biochem Pharmacol. 1998 Apr 1;55(7):1091-7 [9605432.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1274-81 [9849491.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):13-47 [10758303.001]
  • (PMID = 17042060.001).
  • [ISSN] 1332-8166
  • [Journal-full-title] Croatian medical journal
  • [ISO-abbreviation] Croat. Med. J.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Radiation-Sensitizing Agents; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2080466
  •  go-up   go-down


49. Velenik V, Ocvirk J, Oblak I, Anderluh F: A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer. Eur J Surg Oncol; 2010 Mar;36(3):244-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer.
  • BACKGROUND: Neoadjuvant chemoradiotherapy (CRT) reduces local tumor recurrence in locally advanced rectal cancer (LARC).
  • METHODS: Patients with stage II/III LARC received capecitabine 1250 mg/m(2) twice daily for 2 weeks followed by intravenous cetuximab 400 mg/m(2) at week 3, then weekly intravenous 250 mg/m(2) cetuximab plus CRT including capecitabine 825 mg/m(2) twice daily (including weekends during radiotherapy) with radiotherapy of 45 Gy (25 x 1.8 Gy), 5 days a week for 5 weeks.
  • Total sphincter preservation rate was 76%, and 53% in 17 patients whose tumors were located within 5 cm from the anal verge.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20042310.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Prodrugs; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab; U3P01618RT / Fluorouracil
  •  go-up   go-down


50. Nabeshima K, Machimura T, Wasada M, Takayasu H, Ogoshi K, Makuuchi H: A case of primary jejunal cancer diagnosed by preoperative small intestinal endoscopy. Tokai J Exp Clin Med; 2008 Apr;33(1):42-5
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of primary jejunal cancer diagnosed by preoperative small intestinal endoscopy.
  • Small intestinal endoscopy (XSIF-240 endoscope, Olympus Inc.) revealed stenosis related to an epithelially protruding lesion with an irregular surface in the jejunum on the anal side of the horizontal duodenal peduncle.
  • Under a diagnosis of primary jejunum cancer, Partial resection of the jejunum and partial resection of the transverse colon was performed.
  • Postoperatively, the stage was evaluated as III (T3, N1, M0).
  • We report a patient with primary jejunum cancer in whom a definitive diagnosis was made before surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21318964.001).
  • [ISSN] 2185-2243
  • [Journal-full-title] The Tokai journal of experimental and clinical medicine
  • [ISO-abbreviation] Tokai J. Exp. Clin. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


51. Chamlou R, Parc Y, Simon T, Bennis M, Dehni N, Parc R, Tiret E: Long-term results of intersphincteric resection for low rectal cancer. Ann Surg; 2007 Dec;246(6):916-21; discussion 921-2
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of intersphincteric resection for low rectal cancer.
  • INTRODUCTION: In the treatment of very low rectal cancer, a distal resection margin of more than 1 cm can be obtained by partial internal sphincteric resection, allowing a sphincter preserving surgery.
  • Thus, intersphincteric resection (ISR) has been proposed as an alternative to abdominoperineal resection for selected low rectal cancer.
  • Cancer-related survival and locoregional recurrence rates were calculated using the Kaplan-Meier method.
  • RESULTS: Ninety patients (59 males, 31 females) with a tumor at a median distance of 35 mm (range, 22-52) from the anal verge had an ISR.
  • Thirteen patients (14.4%) died of cancer recurrence.
  • In univariate analysis, overall survival was significantly influenced by pTNM stage and T stage (pT 1-2 vs. 3-4: P = 0.008 and stage I-II vs. III-IV: P = 0.03).
  • After adjustment for age, gender, tumor level, and pTNM stage, preoperative radiotherapy was the only factor associated with a risk of fecal incontinence [OR (IC 95%) = 3.1 (1.0-9.0), P = 0.04].
  • [MeSH-major] Adenocarcinoma / epidemiology. Anal Canal / surgery. Colectomy / methods. Rectal Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043092.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Park IJ, Choi GS, Lim KH, Kang BM, Jun SH: Multidimensional analysis of the learning curve for laparoscopic resection in rectal cancer. J Gastrointest Surg; 2009 Feb;13(2):275-81
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidimensional analysis of the learning curve for laparoscopic resection in rectal cancer.
  • BACKGROUND: We attempted to assess the learning curve for laparoscopic resection for rectal cancer.
  • METHOD: We included 381 patients who underwent laparoscopic resection for rectal cancer between December 2002 and December 2007.
  • For the patients with stage I-III tumors, the local recurrence rate was 4.4% and the overall recurrence rate was 22.9%.
  • CONCLUSION: The learning curve for laparoscopic surgery for rectal cancer changed over time.
  • [MeSH-minor] Aged. Anal Canal / surgery. Anastomosis, Surgical / adverse effects. Cohort Studies. Colon / surgery. Female. Humans. Male. Middle Aged. Retrospective Studies. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2005 Jul;6(7):477-84 [15992696.001]
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Arch Surg. 1997 Jan;132(1):41-4; discussion 45 [9006551.001]
  • [Cites] Surg Oncol. 2007 Dec;16 Suppl 1:S113-6 [18054221.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):666-72 [9708929.001]
  • [Cites] Dis Colon Rectum. 2007 Apr;50(4):464-71 [17195085.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):979-94 [10888773.001]
  • [Cites] Ann Surg. 2005 Jul;242(1):83-91 [15973105.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1718-26 [15894098.001]
  • [Cites] Dis Colon Rectum. 2006 Aug;49(8):1108-15 [16763756.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3061-8 [17634484.001]
  • [Cites] Br J Surg. 2003 Jul;90(7):867-71 [12854115.001]
  • [Cites] Dis Colon Rectum. 2001 Feb;44(2):217-22 [11227938.001]
  • [Cites] Surg Endosc. 2002 Jan;16(1):7-13 [11961595.001]
  • [Cites] Ann Surg. 2003 Mar;237(3):335-42 [12616116.001]
  • [Cites] Dis Colon Rectum. 1996 Oct;39(10 Suppl):S14-9 [8831541.001]
  • [Cites] Dis Colon Rectum. 2004 Jul;47(7):1145-9; discussion 1149-50 [15164243.001]
  • [Cites] Dis Colon Rectum. 1997 May;40(5):592-6 [9152190.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Am Surg. 1995 Aug;61(8):681-5 [7618806.001]
  • [Cites] Dis Colon Rectum. 2008 Apr;51(4):385-91 [18219531.001]
  • [Cites] Surg Endosc. 2004 Aug;18(8):1211-5 [15457380.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10):1371-8; discussion 1378-9 [14530677.001]
  • [Cites] World J Surg. 2007 Sep;31(9):1827-34 [17623232.001]
  • [Cites] Am J Surg. 2004 Jan;187(1):47-51 [14706585.001]
  • [Cites] Surg Endosc. 1995 Nov;9(11):1179-83 [8553229.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):458-63 [11923600.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):315-21 [11289275.001]
  • [Cites] World J Surg. 1996 Mar-Apr;20(3):277-81; discussion 282 [8661831.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1261-6 [14515297.001]
  • [Cites] Am J Surg. 2008 Feb;195(2):233-8 [18083137.001]
  • (PMID = 18941844.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Zamboni BA, Yothers G, Choi M, Fuller CD, Dignam JJ, Raich PC, Thomas CR Jr, O'Connell MJ, Wolmark N, Wang SJ: Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07. J Clin Oncol; 2010 May 20;28(15):2544-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07.
  • PURPOSE: Colon cancer overall survival (OS) is usually computed from the time of diagnosis.
  • We extend the concept of CS to condition on the set of patients alive, recurrence-free, and second primary cancer-free (disease-free survival [OS|DFS]).
  • PATIENTS AND METHODS: Using data from National Surgical Adjuvant Breast and Bowel Project trials C-03 through C-07, 5-year OS|DFS was calculated on patients who were disease free up to 5 years after diagnosis, stratified by age, stage, nodal status, and performance status (PS).
  • RESULTS: For stage II, OS|DFS improved from 87% to 92% at 5 years.
  • For stage III, OS|DFS improved from 69% to 88%.
  • CONCLUSION: Prognosis improves over time for almost all groups of patients with colon cancer, especially those with positive nodes.
  • [MeSH-minor] Age Factors. Aged. Clinical Trials, Phase III as Topic. Disease-Free Survival. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Middle Aged. Prognosis. Quality Assurance, Health Care / methods. Randomized Controlled Trials as Topic. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3553-9 [10550154.001]
  • [Cites] Lifetime Data Anal. 2008 Dec;14(4):447-63 [18836831.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2211-9 [11596040.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3035-40 [12915592.001]
  • [Cites] Surg Neurol. 2003 Nov;60(5):402-6; discussion 406 [14572960.001]
  • [Cites] Oncologist. 2003;8(6):541-52 [14657533.001]
  • [Cites] Eur J Cancer. 2004 May;40(8):1233-43 [15110888.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]
  • [Cites] Semin Surg Oncol. 1994 Jan-Feb;10(1):2-6 [8115782.001]
  • [Cites] Cancer. 1995 Jul 15;76(2):237-42 [8625098.001]
  • [Cites] J Clin Epidemiol. 1997 Nov;50(11):1289-96 [9393385.001]
  • [Cites] Dis Colon Rectum. 1998 Sep;41(9):1097-106 [9749492.001]
  • [Cites] J Natl Cancer Inst. 1998 Dec 2;90(23):1810-6 [9839521.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):485-91 [10023719.001]
  • [Cites] Breast Cancer Res Treat. 1998;51(3):239-53 [10068082.001]
  • [Cites] Chest. 1999 Sep;116(3):697-703 [10492274.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8664-70 [16260700.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2059-64 [16648506.001]
  • [Cites] Cancer. 2006 May 15;106(10):2165-70 [16586498.001]
  • [Cites] Oncologist. 2006 Jun;11(6):624-9 [16794241.001]
  • [Cites] Cancer. 2007 Apr 1;109(7):1331-43 [17326199.001]
  • [Cites] J Thorac Oncol. 2007 Mar;2(3):180-90 [17410040.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2198-204 [17470851.001]
  • [Cites] Ann Oncol. 2007 Aug;18(8):1408-13 [17693654.001]
  • [Cites] Gastric Cancer. 2007;10(3):153-8 [17922092.001]
  • [Cites] Gynecol Oncol. 2008 May;109(2):203-9 [18329082.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):257-64 [11263506.001]
  • (PMID = 20406942.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10CA-69974; United States / NCI NIH HHS / CA / U10 CA012027; United States / NCI NIH HHS / CA / U10 CA069651; United States / NCI NIH HHS / CA / U10CA-37377; United States / NCI NIH HHS / CA / U10 CA069974; United States / NCI NIH HHS / CA / U10CA-12027; United States / NCI NIH HHS / CA / U10 CA037377; United States / NCI NIH HHS / CA / U10CA-69651
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2881729
  •  go-up   go-down


54. Yoo JH, Hasegawa H, Ishii Y, Nishibori H, Watanabe M, Kitajima M: Long-term outcome of per anum intersphincteric rectal dissection with direct coloanal anastomosis for lower rectal cancer. Colorectal Dis; 2005 Sep;7(5):434-40
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of per anum intersphincteric rectal dissection with direct coloanal anastomosis for lower rectal cancer.
  • With direct coloanal anastomosis for cases of lower rectal cancer in which the distal surgical margin is difficult to secure by the double stapling technique.
  • Of these, two patients (one stage 0 and one stage IV) were excluded from the analysis of oncological outcome.
  • There was an association between distant metastasis and TNM or pT stage.
  • The overall survival rates for stage I, II and III were 85%, 80% and 89%, respectively.
  • CONCLUSION: The surgical indications of this operation should be limited to patients with T1 rectal cancer or tumours less than 3 cm.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Fecal Incontinence / epidemiology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Proctocolectomy, Restorative. Rectum / surgery. Surveys and Questionnaires. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16108877.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


59. Park EM, Ramnath N, Yang GY, Ahn JY, Park Y, Lee TY, Shin HS, Yu J, Ip C, Park YM: High superoxide dismutase and low glutathione peroxidase activities in red blood cells predict susceptibility of lung cancer patients to radiation pneumonitis. Free Radic Biol Med; 2007 Jan 15;42(2):280-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High superoxide dismutase and low glutathione peroxidase activities in red blood cells predict susceptibility of lung cancer patients to radiation pneumonitis.
  • Radiation pneumonitis is an unpredictable complication of radiotherapy for lung cancer and a condition which can cause significant morbidity.
  • Superoxide dismutase (SOD), glutathione peroxidase (GPX), and catalase (CAT) activities and glutathione in RBC were measured at baseline and then weekly for 6 weeks of treatment in 15 eligible patients receiving concurrent chemo-radiotherapy for unresectable stage III NSCLC.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiat Res. 1997 Feb;147(2):245-56 [9008217.001]
  • [Cites] J Natl Cancer Inst. 1996 Sep 4;88(17):1210-5 [8780630.001]
  • [Cites] Exp Lung Res. 1998 May-Jun;24(3):321-37 [9635254.001]
  • [Cites] Free Radic Biol Med. 1998 Jul 1;25(1):79-86 [9655525.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2692-9 [10561343.001]
  • [Cites] J Cell Physiol. 2000 Apr;183(1):100-7 [10699971.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1029-35 [9719112.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):469-78 [9806503.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):318-28 [15667949.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):862-71 [15936571.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 1;49(3):641-8 [11172944.001]
  • [Cites] Int J Radiat Biol. 2000 Apr;76(4):511-6 [10815631.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):899-908 [11429217.001]
  • [Cites] Radiat Res. 2002 Mar;157(3):256-65 [11839087.001]
  • [Cites] Semin Radiat Oncol. 2002 Jan;12(1 Suppl 1):26-33 [11917281.001]
  • [Cites] J Natl Cancer Inst. 2002 May 15;94(10):733-41 [12011223.001]
  • [Cites] Free Radic Biol Med. 2003 Mar 15;34(6):689-95 [12633746.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):758-67 [14967431.001]
  • [Cites] Radiother Oncol. 2004 May;71(2):183-9 [15110452.001]
  • [Cites] Anal Biochem. 1989 May 15;179(1):8-18 [2547324.001]
  • [Cites] Radiat Res. 1991 Jun;126(3):349-56 [1852022.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 May 15;29(2):383-6 [8195038.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6 [7713792.001]
  • [Cites] Semin Oncol. 1995 Aug;22(4 Suppl 9):34-7 [7644926.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2606-12 [7595714.001]
  • [Cites] Radiat Res. 1996 Jun;145(6):762-7 [8643837.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1071-6 [8648359.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6432-7 [9177235.001]
  • (PMID = 17189833.001).
  • [ISSN] 0891-5849
  • [Journal-full-title] Free radical biology & medicine
  • [ISO-abbreviation] Free Radic. Biol. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016056-30; United States / NCI NIH HHS / CA / CA109480; United States / NCI NIH HHS / CA / R01 CA109480; United States / NCI NIH HHS / CA / P30 CA016056; United States / NCI NIH HHS / CA / CA16056; United States / NCI NIH HHS / CA / R01 CA109480-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.11.1.9 / Glutathione Peroxidase; EC 1.15.1.1 / Superoxide Dismutase
  • [Other-IDs] NLM/ NIHMS16140; NLM/ PMC1892164
  •  go-up   go-down


60. Morino M, Giraudo G: Laparoscopic total mesorectal excision-the Turin experience. Recent Results Cancer Res; 2005;165:167-79
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Improved local control and survival rates in the treatment of rectal cancer have been reported after total mesorectal excision (TME).
  • We performed an analysis of TME for rectal cancer by laparoscopic approach during a prospective nonrandomized trial.
  • The distal limit of rectal neoplasm was on average 5.4 cm (range 3-12) from the anal verge.
  • During this period, 15.1% (14/93) died of cancer and 7.5% (7/93) are alive with metastatic disease.
  • The locoregional pelvic recurrence rate was 2.1% (2/93): 1 stage II at 12 months and 1 stage III at 18 postoperative months, respectively.
  • Further studies and possibly randomized series will be necessary to evaluate long-term clinical outcome in cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15865031.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


61. Kim SH, Park IJ, Joh YG, Hahn KY: Laparoscopic resection for rectal cancer: a prospective analysis of thirty-month follow-up outcomes in 312 patients. Surg Endosc; 2006 Aug;20(8):1197-202
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic resection for rectal cancer: a prospective analysis of thirty-month follow-up outcomes in 312 patients.
  • BACKGROUND: This study aimed to prospectively evaluate operative safety and mid-term oncologic outcomes of laparoscopic rectal cancer resection performed by a single surgeon.
  • 257 patients (82.4%) had tumors located below 12 cm from the anal verge.
  • Distribution of TNM stages was 0:I:II:III:IV = 4.2%:17.9%:32.4%:37.2%:8.3%.
  • With a mean follow-up of 30 months in the stage I-III patients, the local recurrence rate was 2.9%.
  • CONCLUSION: Laparoscopic resection of rectal cancer provided safe operative parameters and adequate mid-term oncologic outcomes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Surg Endosc. 2004 Oct;18(10):1457-62 [15791369.001]
  • [Cites] Arch Surg. 1998 Aug;133(8):894-9 [9711965.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1718-26 [15894098.001]
  • [Cites] Dis Colon Rectum. 2001 Apr;44(4):473-83; discussion 483-6 [11330574.001]
  • [Cites] Lancet. 2004 Apr 10;363(9416):1187-92 [15081650.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):260-8 [15273550.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):800-11 [9637543.001]
  • [Cites] Surg Endosc. 2005 Jun;19(6):757-66 [15868256.001]
  • [Cites] Br J Surg. 2001 Nov;88(11):1501-5 [11683749.001]
  • [Cites] Colorectal Dis. 2005 Jul;7(4):403-5 [15932567.001]
  • [Cites] Ann Surg. 2003 Mar;237(3):335-42 [12616116.001]
  • [Cites] Surgery. 1998 Oct;124(4):612-7; discussion 617-8 [9780979.001]
  • [Cites] Ann Surg. 1999 Oct;230(4):544-52; discussion 552-4 [10522724.001]
  • [Cites] Int J Colorectal Dis. 2005 Sep;20(5):428-33 [15800782.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] Surg Endosc. 2002 Jun;16(6):989-95 [12163970.001]
  • [Cites] Br J Surg. 1994 Aug;81(8):1224-6 [7953369.001]
  • [Cites] Surg Gynecol Obstet. 1984 Jan;158(1):33-8 [6691164.001]
  • [Cites] Br J Surg. 2005 Feb;92(2):230-4 [15609379.001]
  • [Cites] Surg Endosc. 2004 Feb;18(2):281-9 [14691716.001]
  • (PMID = 16865622.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


62. Thall PF: A review of phase 2-3 clinical trial designs. Lifetime Data Anal; 2008 Mar;14(1):37-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is followed by descriptions of some particular phase 2-3 designs that have been proposed, including two-stage designs to evaluate one experimental treatment, a design that accommodates both frontline and salvage therapy in oncology, two-stage select-and-test designs that evaluate several experimental treatments, dose-ranging designs, and a seamless phase 2-3 design based on both early response-toxicity outcomes and later event times.
  • [MeSH-major] Clinical Trials, Phase II as Topic / methods. Clinical Trials, Phase III as Topic / methods. Research Design

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7199-206 [16192604.001]
  • [Cites] Stat Med. 1995 Feb 28;14(4):357-79 [7746977.001]
  • [Cites] Stat Med. 2005 May 30;24(10):1455-81 [15586395.001]
  • [Cites] Biometrics. 1982 Mar;38(1):143-51 [7082756.001]
  • [Cites] Stat Med. 1986 Sep-Oct;5(5):459-64 [3787000.001]
  • [Cites] Stat Med. 2007 Nov 20;26(26):4687-702 [17427204.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Stat Med. 2000 Apr 30;19(8):1011-28 [10790677.001]
  • [Cites] Cancer Treat Rep. 1985 Dec;69(12):1375-81 [4075313.001]
  • [Cites] Clin Trials. 2004 Feb;1(1):9-20 [16281458.001]
  • [Cites] Biometrics. 1989 Jun;45(2):537-47 [2765637.001]
  • [Cites] Stat Med. 1994 Mar 15-Apr 15;13(5-7):417-29 [8023026.001]
  • [Cites] Control Clin Trials. 1988 Jun;9(2):107-18 [3396362.001]
  • [Cites] Blood. 2003 Jul 15;102(2):442-8 [12560224.001]
  • [Cites] Biometrics. 2002 Dec;58(4):823-31 [12495136.001]
  • [Cites] Biometrics. 1995 Dec;51(4):1372-83 [8589229.001]
  • [Cites] Biometrics. 1987 Dec;43(4):865-74 [3427171.001]
  • [Cites] Biometrics. 2004 Sep;60(3):684-93 [15339291.001]
  • [Cites] Biometrics. 1994 Jun;50(2):337-49 [7980801.001]
  • [Cites] Clin Trials. 2007;4(2):113-24 [17456511.001]
  • [Cites] Cancer Treat Rep. 1985 Oct;69(10):1147-54 [4042093.001]
  • [Cites] J Natl Cancer Inst. 1992 Mar 18;84(6):407-14 [1531682.001]
  • [Cites] J Chronic Dis. 1961 Apr;13:346-53 [13704181.001]
  • [Cites] Stat Med. 1990 Mar;9(3):215-28 [2188324.001]
  • [Cites] Stat Med. 1988 May;7(5):571-9 [3387716.001]
  • (PMID = 17763973.001).
  • [ISSN] 1380-7870
  • [Journal-full-title] Lifetime data analysis
  • [ISO-abbreviation] Lifetime Data Anal
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 83932
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


63. Hessien MH, El-Sharkawi IM, El-Barbary AA, El-Beltagy DM, Snyder N: Non-invasive index of liver fibrosis induced by alcohol, thioacetamide and Schistosomal infection in mice. BMC Gastroenterol; 2010;10:53
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The following methods were employed: (i) The METAVIR system was utilized to grade and stage liver inflammation and fibosis;.
  • (ii) Determination of hepatic hydroxyproline and collagen; and (iii) Derivation of a new hepatic fibrosis index from the induced changes, and its prospective validation in a group of 70 mice.
  • These parameters were highly correlated with both the histological stage and the grade.
  • They were combined in a logarithmic formula, which non-invasively scores the severity of liver fibrosis through a range (0 to 2), starting with healthy liver (corresponding to stage 0) to advanced fibrosis (corresponding stage 3).Receiver operating characteristic curves (ROC) for the accuracy of the index to predict the histological stages demonstrated that the areas under the curve (AUC) were 0.954, 0.979 and 0.99 for index values corresponding to histological stages 1, 2 and 3, respectively.
  • Also, the index was correlated with stage and grade, (0.947 and 0.859, respectively).
  • The AUROC was 0.869 and there was good correlation with the stage of fibrosis and grade of inflammation.

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • Hazardous Substances Data Bank. THIOACETAMIDE .
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 1999 Dec;30(6):1529-30 [10610352.001]
  • [Cites] Hepatology. 2009 Jun;49(6):1821-7 [19291784.001]
  • [Cites] N Engl J Med. 2001 Feb 15;344(7):495-500 [11172192.001]
  • [Cites] Lancet. 2001 Apr 7;357(9262):1069-75 [11297957.001]
  • [Cites] Hum Exp Toxicol. 2001 May;20(5):251-4 [11476157.001]
  • [Cites] Hepatology. 2002 Oct;36(4 Pt 1):986-92 [12297848.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2614-8 [12385448.001]
  • [Cites] Hepatology. 1997 Dec;26(6):1393-8 [9397976.001]
  • [Cites] Hepatology. 1999 Jan;29(1):14-20 [9862843.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] J Hepatol. 2003 Aug;39(2):222-30 [12873819.001]
  • [Cites] J Hepatol. 2003 Aug;39(2):239-44 [12873821.001]
  • [Cites] Hepatology. 2003 Aug;38(2):518-26 [12883497.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2003 Feb;2(1):69-72 [14607650.001]
  • [Cites] Anal Biochem. 1979 Jun;95(2):351-8 [36810.001]
  • [Cites] Res Exp Med (Berl). 1980;177(3):201-11 [6449727.001]
  • [Cites] Pharmacol Ther. 1985;29(1):129-56 [3914644.001]
  • [Cites] Pharmacol Toxicol. 1987 Mar;60(3):171-4 [3588511.001]
  • [Cites] Exp Pathol. 1988;34(4):229-36 [2853079.001]
  • [Cites] Hepatology. 1996 Aug;24(2):289-93 [8690394.001]
  • [Cites] Arch Biochem Biophys. 1959 May;82(1):70-7 [13650640.001]
  • [Cites] Gastroenterology. 2005 Feb;128(2):343-50 [15685546.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Feb;3(2):167-74 [15704051.001]
  • [Cites] Alcohol Clin Exp Res. 2006 Aug;30(8):1429-35 [16899047.001]
  • [Cites] J Hepatol. 2007 May;46(5):775-82 [17321634.001]
  • [Cites] Clin Chim Acta. 2007 Jun;381(2):119-23 [17442291.001]
  • [Cites] Rinsho Byori. 2007 Aug;55(8):751-7 [17882797.001]
  • [Cites] Hepatology. 2008 Feb;47(2):455-60 [18038452.001]
  • [Cites] Cancer Res. 2008 Mar 15;68(6):2033-42 [18339886.001]
  • [Cites] Chest. 2008 May;133(5):1101-6 [18071010.001]
  • [Cites] Anal Biochem. 2000 Oct 1;285(1):16-20 [10998259.001]
  • (PMID = 20515488.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 075T165X8M / Thioacetamide; 3K9958V90M / Ethanol; 9007-34-5 / Collagen; EC 2.3.2.2 / gamma-Glutamyltransferase; GAN16C9B8O / Glutathione; RFM9X3LJ49 / Bilirubin; RMB44WO89X / Hydroxyproline
  • [Other-IDs] NLM/ PMC2894747
  •  go-up   go-down


64. Matsopoulos GK, Mouravliansky NA, Asvestas PA, Delibasis KK, Kouloulias V: Thoracic non-rigid registration combining self-organizing maps and radial basis functions. Med Image Anal; 2005 Jun;9(3):237-54
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An automatic three-dimensional non-rigid registration scheme is proposed in this paper and applied to thoracic computed tomography (CT) data of patients with stage III non-small cell lung cancer (NSCLC).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radiography. Imaging, Three-Dimensional / methods. Lung Neoplasms / radiography. Pattern Recognition, Automated / methods. Radiographic Image Interpretation, Computer-Assisted / methods. Radiography, Thoracic / methods. Subtraction Technique

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15854844.001).
  • [ISSN] 1361-8415
  • [Journal-full-title] Medical image analysis
  • [ISO-abbreviation] Med Image Anal
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article
  • [Publication-country] England
  •  go-up   go-down


65. Sinha S, Sinha N, Bandyopadhyay R, Mondal SK: Robinson's cytological grading on aspirates of breast carcinoma: Correlation with Bloom Richardson's histological grading. J Cytol; 2009 Oct;26(4):140-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robinson's cytological grading on aspirates of breast carcinoma: Correlation with Bloom Richardson's histological grading.
  • BACKGROUND: Cytological grading (CG) on aspirates of breast carcinoma is a useful tool for surgical maneuver and prognosis.
  • AIMS: An endeavor was made to use CG on aspirates of breast carcinoma using Robinson's grade and to correlate it with Bloom Richardsons' histopathological grading.
  • MATERIALS AND METHODS: A total of 59 patients of breast carcinoma, aged 28-57 years, were aspirated and the smears were graded using Robinson's criteria.
  • For grade I and II tumors, there was substantial strength of agreement between cytology and histopathology, while in grade III, the concordance was nearly perfect.
  • Lymph node metastasis was observed in three with cytological grade II, 28 of grade III and none of grade I.
  • All grade I had stage A, two of grade II had stage B, while all grade III had either stage B or stage C disease.
  • CONCLUSIONS: Thus, CG of breast carcinoma correlates well with histopathological grading and may well be useful as a prognostic marker.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Anal Quant Cytol Histol. 1987 Dec;9(6):480-4 [2829937.001]
  • [Cites] Lancet. 1994 Apr 16;343(8903):947-9 [7909010.001]
  • [Cites] Diagn Cytopathol. 1997 Apr;16(4):295-311 [9143822.001]
  • [Cites] Cancer. 1997 Feb 25;81(1):16-21 [9100536.001]
  • [Cites] Diagn Cytopathol. 1995 Oct;13(3):260-5 [8575287.001]
  • [Cites] Diagn Cytopathol. 1995 Dec;13(5):388-95 [8834313.001]
  • [Cites] Diagn Cytopathol. 1996 Aug;15(2):116-20 [8872432.001]
  • [Cites] Diagn Cytopathol. 1994;10(3):203-8 [8050325.001]
  • (PMID = 21938177.001).
  • [ISSN] 0974-5165
  • [Journal-full-title] Journal of cytology
  • [ISO-abbreviation] J Cytol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3167998
  • [Keywords] NOTNLM ; Bloom Richardson's grading / Breast carcinoma / Robinson's grading / fine needle aspiration cytology
  •  go-up   go-down


66. Park IJ, Choi GS, Lim KH, Kang BM, Jun SH: Different patterns of lymphatic spread of sigmoid, rectosigmoid, and rectal cancers. Ann Surg Oncol; 2008 Dec;15(12):3478-83

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: We tried to evaluate the clinicopathological characteristics of rectosigmoid cancer compared with those of sigmoid and rectal cancer.
  • METHODS: We collected data on patients who underwent curative resections for sigmoid (399; SC group), rectosigmoid (175; RS group), and upper rectal cancer (453; RA group) between June 1996 and December 2007.
  • RESULTS: The mean distance from the anal verge was 12.5 cm for rectosigmoid cancer, 13 cm for sigmoid cancer, and 9.8 cm for rectal cancer.
  • For stage III disease, the local recurrence rate was significantly higher in the RA group; the disease-free survival rate was higher in the SC group, and the RS group showed results similar to those of the RA group.
  • CONCLUSION: Clinicopathological characteristics of rectosigmoid cancer were similar to those of sigmoid or rectal cancer.
  • For lymphatic spreads, it was different from sigmoid or rectal cancer and more frequently metastasized to pararectal nodes.
  • Oncologic results were slightly unfavorable to sigmoid colon, and showed data similar to those of rectal cancer.
  • Therefore, rectosigmoid cancer was a "real" classification of colorectal cancer with unique lymphatic spread.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma, Mucinous / secondary. Carcinoma, Signet Ring Cell / secondary. Lymph Nodes / pathology. Rectal Neoplasms / pathology. Sigmoid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2010 Jan;17(1):346-7 [19841983.001]
  • (PMID = 18830668.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Liang JT, Lai HS, Lee PH: Multimedia article. Laparoscopic abdominoperineal resection for lower rectal cancers: how do we do it? Surg Endosc; 2006 Apr;20(4):695-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The appropriateness of the laparoscopic approach for the resection of rectal cancer has been controversial, although it is well established in colon cancer.
  • METHODS: Patients with lower rectal adenocarcinoma located within 6 cm above the anal verge were recruited and subjected to laparoscopic APR.
  • Physical status (American Society of Anesthesiology classification) was class I in 12, class II in eight, and class III in two patients.
  • Two patients were in pathologic TNM stage I, 14 in stage II, and six in stage III.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Dis Colon Rectum. 2002 Nov;45(11):1481-5 [12432295.001]
  • [Cites] World J Surg. 2002 Mar;26(3):377-83 [11865378.001]
  • [Cites] Lancet. 2004 Apr 10;363(9416):1187-92 [15081650.001]
  • [Cites] J Am Coll Surg. 1998 Jul;187(1):46-54; discussion 54-5 [9660024.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2000 Feb;10(1):47-53 [10706303.001]
  • [Cites] World J Surg. 2003 Feb;27(2):190-6 [12616435.001]
  • [Cites] Ann Surg. 1967 Sep;166(3):420-7 [6039601.001]
  • (PMID = 16502195.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article; Video-Audio Media
  • [Publication-country] Germany
  •  go-up   go-down


68. Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J, Swerts K, Bravo S, Scaruffi P, Tonini GP, De Bernardi B, Noguera R, Piqueras M, Cañete A, Castel V, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Michon J, Combaret V, Fischer M, Oberthuer A, Ambros PF, Beiske K, Bénard J, Marques B, Rubie H, Kohler J, Pötschger U, Ladenstein R, Hogarty MD, McGrady P, London WB, Laureys G, Speleman F, Vandesompele J: Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol; 2009 Jul;10(7):663-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These results were confirmed in the validation study, in which the signature was also independently statistically significant in a model adjusted for MYCN status, age, International Neuroblastoma Staging System stage, ploidy, International Neuroblastoma Pathology Classification grade of differentiation, and mitosis karyorrhexis index (odds ratios between 4.81 and 10.53 depending on the model for overall survival and 3.68 [95% CI 2.01-6.71] for progression-free survival).
  • FUNDING: The Belgian Foundation Against Cancer, the Children Cancer Fund Ghent, the Belgian Society of Paediatric Haematology and Oncology, the Belgian Kid's Fund and the Fondation Nuovo-Soldati (JV), the Fund for Scientific Research Flanders (KDP, JH), the Fund for Scientific Research Flanders, the Institute for the Promotion of Innovation by Science and Technology in Flanders, Strategisch basisonderzoek, the Fondation Fournier Majoie pour l'Innovation, the Instituto Carlos III, the Italian Neuroblastoma Foundation, the European Community under the FP6, and the Belgian programme of Interuniversity Poles of Attraction.

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Eur J Cancer. 2013 Nov;49(17):3671-9 [23907002.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] Cancer Cell. 2002 Nov;2(5):377-86 [12450793.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1599-609 [15090470.001]
  • [Cites] Lancet. 2005 Feb 19-25;365(9460):671-9 [15721472.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):337-50 [15837623.001]
  • [Cites] Oncogene. 2005 Nov 24;24(53):7902-12 [16103881.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):131-8 [16397034.001]
  • [Cites] Mol Aspects Med. 2006 Apr-Jun;27(2-3):126-39 [16469371.001]
  • [Cites] Anal Biochem. 2006 Apr 15;351(2):308-10 [16524557.001]
  • [Cites] Cancer Cell. 2006 May;9(5):333-9 [16697954.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6050-62 [16778177.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Jul;28(7):412-7 [16825985.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5070-8 [17075126.001]
  • [Cites] Genome Biol. 2006;7(9):R84 [16989664.001]
  • [Cites] N Engl J Med. 2007 Jan 4;356(1):11-20 [17202451.001]
  • [Cites] N Engl J Med. 2007 Jan 18;356(3):217-26 [17229949.001]
  • [Cites] Lancet. 2007 Jun 23;369(9579):2106-20 [17586306.001]
  • [Cites] BMC Genomics. 2008;9:177 [18416850.001]
  • [Cites] Oncogene. 2008 May 22;27(23):3329-38 [18084322.001]
  • [Cites] Curr Opin Genet Dev. 2008 Feb;18(1):3-10 [18325755.001]
  • [Cites] BMC Cancer. 2008;8:173 [18559103.001]
  • [Cites] J Natl Cancer Inst. 2008 Jul 2;100(13):940-9 [18577749.001]
  • [Cites] Cancer. 2008 Sep 15;113(6):1412-22 [18671248.001]
  • [Cites] Br J Cancer. 2008 Oct 7;99(7):1027-33 [18766186.001]
  • [Cites] Cancer Res. 2008 Dec 1;68(23):9735-45 [19047152.001]
  • [Cites] Nucleic Acids Res. 2009 Jan;37(Database issue):D942-5 [18948285.001]
  • [Cites] J Clin Oncol. 2009 Mar 1;27(7):1034-40 [19171711.001]
  • [Cites] J Clin Oncol. 2009 Mar 1;27(7):1014-9 [19171715.001]
  • [CommentIn] Lancet Oncol. 2009 Jul;10(7):641-2 [19573794.001]
  • (PMID = 19515614.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA114766-05; United States / NCI NIH HHS / CA / CA114766-05; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U24 CA114766; United States / NCI NIH HHS / CA / U10 CA098543-08; None / None / / U10 CA098543-08; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA098413-08; None / None / / U10 CA098413-08
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS264157; NLM/ PMC3045079
  •  go-up   go-down


69. Balakrishnan K, Verma D, O'Brien S, Kilpatrick JM, Chen Y, Tyler BF, Bickel S, Bantia S, Keating MJ, Kantarjian H, Gandhi V, Ravandi F: Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. Blood; 2010 Aug 12;116(6):886-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six had Rai stage III to IV and were previously heavily treated (median prior therapy = 5).

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2001 Apr 26;165(2):195-200 [11275369.001]
  • [Cites] Blood. 2010 Aug 19;116(7):1083-91 [20442367.001]
  • [Cites] Int Immunopharmacol. 2001 Jun;1(6):1199-210 [11407314.001]
  • [Cites] Leuk Lymphoma. 2002 Sep;43(9):1755-62 [12685828.001]
  • [Cites] Int Immunopharmacol. 2003 Apr;3(4):541-8 [12689658.001]
  • [Cites] Int Immunopharmacol. 2003 Jun;3(6):879-87 [12781704.001]
  • [Cites] Leukemia. 2004 Mar;18(3):385-93 [14737075.001]
  • [Cites] J Biol Chem. 1969 Feb 25;244(4):644-7 [5768862.001]
  • [Cites] Lancet. 1975 May 3;1(7914):1010-3 [48676.001]
  • [Cites] J Clin Invest. 1980 Jan;65(1):103-8 [6765955.001]
  • [Cites] Cancer Res. 1980 Mar;40(3):588-91 [6937239.001]
  • [Cites] Annu Rev Biochem. 1981;50:845-77 [6267992.001]
  • [Cites] Br J Haematol. 1981 Sep;49(1):23-8 [6974004.001]
  • [Cites] Adv Exp Med Biol. 1986;195 Pt B:191-9 [3094325.001]
  • [Cites] Anal Biochem. 1989 Aug 1;180(2):222-6 [2554751.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Biochemistry. 1998 Jun 16;37(24):8615-21 [9628722.001]
  • [Cites] Immunopharmacology. 1998 Jul;40(1):1-9 [9776473.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3607-15 [9817282.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4253-60 [16131572.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2392-8 [16778146.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1098-105 [18309944.001]
  • [Cites] Leuk Res. 2008 Aug;32(8):1268-78 [18279955.001]
  • [Cites] Blood. 2009 Aug 20;114(8):1563-75 [19541822.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4593-8 [11287638.001]
  • (PMID = 20427701.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00289549
  • [Grant] United States / NCI NIH HHS / CA / P01 CA081534; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA81534; United States / PHS HHS / / P30-16672
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Purine Nucleosides; 0 / Pyrimidinones; 426X066ELK / forodesine; EC 2.4.2.1 / Purine-Nucleoside Phosphorylase; EC 3.1.3.2 / Phosphoric Monoester Hydrolases; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  • [Other-IDs] NLM/ PMC2924226
  •  go-up   go-down


70. Yasumoto T, Shimizu J, Watanabe N, Inada M, Nakata S, Sato M, Hayashi S, Dono K, Kitada M, Shimano T: [A case of bile peritonitis caused by jejunal perforation after radiofrequency ablation for the multiple liver metastases from cholangiocarcinoma successfully treated with various interventional radiological procedures after pancreatoduodenectomy]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2093-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The lesion was judged to be T3, N1, H0, P0, M0 and Stage III, and then he received various treatments including thermotherapy, CD3-activated T lymphocyte therapy.
  • Fifty days after the ablation, T-tube, with which pancreatic fluid and bile was induced from the cecal portion of the anastomosed jejunum to the anal side slipping through the perforated point, was successfully inserted through right flank, and resulted in complete recovery from a major technical complication of the bile peritonitis.

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Small Intestine Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037334.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


71. Slejkovec Z, Falnoga I, Goessler W, van Elteren JT, Raml R, Podgornik H, Cernelc P: Analytical artefacts in the speciation of arsenic in clinical samples. Anal Chim Acta; 2008 Jan 21;607(1):83-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Urine and blood samples of cancer patients, treated with high doses of arsenic trioxide were analysed for arsenic species using HPLC-HGAFS and, in some cases, HPLC-ICPMS.
  • The main arsenic species found in urine were As(III), MA and DMA and in blood As(V), MA and DMA.
  • The latter losses may be attributed to precipitation of As(III)-containing proteins/peptides during the methanol/water extraction procedure whereas the former losses were due to loss of specific As(III)-complexing proteins/peptides (e.g. cysteine, metallothionein, reduced GSH, ferritin) on the column (Hamilton PRP-X100) during the separation procedure.
  • Contemporary analytical protocols are not able to completely avoid artefacts due to losses from the sampling to the detection stage so that it is recommended to be careful with the explanation of results, particularly regarding metabolic and pharmacokinetic interpretations, and always aim to compare the sum of species with the total arsenic concentration determined independently.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18155413.001).
  • [ISSN] 1873-4324
  • [Journal-full-title] Analytica chimica acta
  • [ISO-abbreviation] Anal. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


72. Rivera R, Barboglio PG, Hellinger M, Gousse AE: Staging rectourinary fistulas to guide surgical treatment. J Urol; 2007 Feb;177(2):586-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Etiology was rectal injury during open radical prostatectomy in 5 patients, laparoscopic prostatectomy in 1, radiation induced fistula for prostate cancer treatment (brachytherapy and external beam radiation therapy) in 2, neoadjuvant external beam radiation therapy in 2, ischial decubitus ulcer in 3 with spinal cord injury, and cryotherapy and external beam radiation therapy in 1.
  • Cases were staged as stage I--low (less than 4 cm from anal verge and nonirradiated), stage II--high (more than 4 cm from anal verge and nonirradiated), stage III--small (less than 2 cm irradiated fistula), stage IV--large (more than 2 cm irradiated fistula) and stage V--large (ischial decubitus fistula).
  • Diverting colostomy was performed for stages III to V 6 weeks before definitive therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17222638.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Mehta AS, Long RE, Comunale MA, Wang M, Rodemich L, Krakover J, Philip R, Marrero JA, Dwek RA, Block TM: Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of hepatitis C virus-infected individuals with fibrosis and cirrhosis. J Virol; 2008 Feb;82(3):1259-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hepatitis B and C viruses are major causative agents of liver fibrosis, cirrhosis, and liver cancer.
  • Increased lectin reactivity was observed in 100% of the more than 200 individuals with stage III or greater fibrosis and appeared to be correlated with the degree of fibrosis.

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • COS Scholar Universe. author profiles.
  • Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Antivir Ther. 2004 Dec;9(6):1013-26 [15651760.001]
  • [Cites] Arthritis Rheum. 1999 Aug;42(8):1682-90 [10446868.001]
  • [Cites] AIDS. 2005 Mar 4;19(4):381-9 [15750391.001]
  • [Cites] Semin Liver Dis. 2005;25(2):143-54 [15918143.001]
  • [Cites] Immunol Cell Biol. 2005 Dec;83(6):674-86 [16266320.001]
  • [Cites] J Clin Invest. 2005 Nov;115(11):3072-82 [16276416.001]
  • [Cites] J Proteome Res. 2006 Feb;5(2):308-15 [16457596.001]
  • [Cites] J Immunol. 2006 Aug 1;177(3):1737-45 [16849483.001]
  • [Cites] Science. 2006 Aug 4;313(5787):670-3 [16888140.001]
  • [Cites] J Hepatol. 2006 Nov;45(5):744-57 [16979776.001]
  • [Cites] Mol Cell Proteomics. 2006 Oct;5(10):1957-67 [16760258.001]
  • [Cites] Annu Rev Immunol. 2007;25:21-50 [17029568.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 15;104(20):8433-7 [17485663.001]
  • [Cites] Hepatology. 2007 Sep;46(3):618-21 [17879361.001]
  • [Cites] Biotechnol Genet Eng Rev. 1999;16:1-21 [10819075.001]
  • [Cites] J Hepatol. 2001 Dec;35(6):749-55 [11738102.001]
  • [Cites] Hepatology. 2002 Dec;36(6):1349-54 [12447858.001]
  • [Cites] J Hepatol. 2003;39 Suppl 1:S111-5 [14708688.001]
  • [Cites] Proteomics. 2004 Mar;4(3):826-38 [14997503.001]
  • [Cites] J Viral Hepat. 2004 May;11(3):251-6 [15117327.001]
  • [Cites] Nat Med. 2004 Apr;10(4):429-34 [15152612.001]
  • [Cites] Biochem Biophys Res Commun. 1977 Nov 21;79(2):388-95 [412499.001]
  • [Cites] Liver. 1984 Jun;4(3):214-8 [6748875.001]
  • [Cites] Nature. 1985 Aug 1-7;316(6027):452-7 [3927174.001]
  • [Cites] Lancet. 1988 Apr 30;1(8592):966-9 [2896829.001]
  • [Cites] Br J Rheumatol. 1988;27 Suppl 2:162-9 [3135870.001]
  • [Cites] Am J Gastroenterol. 1990 Aug;85(8):1005-8 [2375310.001]
  • [Cites] Blood. 1993 Oct 15;82(8):2485-93 [7691263.001]
  • [Cites] J Hepatol. 1995 Jun;22(6):696-9 [7560864.001]
  • [Cites] Anal Biochem. 1996 Sep 5;240(2):210-26 [8811911.001]
  • [Cites] Curr Opin Biotechnol. 1997 Aug;8(4):488-97 [9265730.001]
  • [Cites] Hepatology. 1997 Sep;26(3 Suppl 1):15S-20S [9305658.001]
  • [Cites] Hepatology. 1997 Sep;26(3 Suppl 1):34S-38S [9305661.001]
  • [Cites] Hepatology. 1997 Sep;26(3 Suppl 1):62S-65S [9305666.001]
  • [Cites] Autoimmunity. 1998;28(1):25-30 [9754811.001]
  • [Cites] Eur J Biochem. 1998 Dec 1;258(2):623-56 [9874230.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):779-84 [15642945.001]
  • (PMID = 18045939.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA120206; United States / NCI NIH HHS / CA / U01 CA084951; United States / NCI NIH HHS / CA / R01 CA120206-01; United States / NCI NIH HHS / CA / UO1 CA084951-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Lectins; 0 / Trisaccharides; 0 / alpha-galactosyl epitope; 0 / fucose-binding lectin
  • [Other-IDs] NLM/ PMC2224448
  •  go-up   go-down


74. Saleh F, Abdeen S: Pathobiological features of breast tumours in the State of Kuwait: a comprehensive analysis. J Carcinog; 2007;6:12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Breast cancer accounts for 30.3% of all cancer types in Kuwaiti women.
  • Grading of invasive carcinomas was done according to the modified Bloom-Richardson-Elston's method, and tumour stage was determined according to the criteria set by the American Joint Committee on Cancer.
  • They were mostly grade II or III, sized 2-5 or > 5 cm, had absent or scanty tumour lymphocytes, and were stage II or III.
  • The in situ tumours were mainly ductal carcinoma (DCIS) of which comedo and cribriform were the major histological subtypes.
  • CONCLUSION: Breast cancer in Kuwait seems to be more aggressive than what is currently seen in Europe, North America, Australia, and parts of Asia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 1998 Feb;11(2):155-68 [9504686.001]
  • [Cites] J Surg Oncol. 2004 Jun 1;86(3):134-40 [15170651.001]
  • [Cites] Breast Cancer Res Treat. 1998;51(3):195-208 [10068079.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):26-35 [15332092.001]
  • [Cites] Eur J Cancer Prev. 2004 Aug;13(4):307-17 [15554559.001]
  • [Cites] Am Surg. 2005 Jan;71(1):22-7; discussion 27-8 [15757052.001]
  • [Cites] Kaohsiung J Med Sci. 2005 May;21(5):197-202 [15960065.001]
  • [Cites] Breast Cancer Res. 2005;7(4):R541-54 [15987461.001]
  • [Cites] Br J Dermatol. 2005 Jul;153(1):18-21 [16029321.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3c):2535-42 [16080489.001]
  • [Cites] J Reprod Immunol. 2005 Oct;67(1-2):35-50 [16111767.001]
  • [Cites] Breast Cancer Res. 2005;7(5):R598-604 [16168103.001]
  • [Cites] Acta Oncol. 1990;29(7):931-4 [1979748.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):944-8 [1988136.001]
  • [Cites] Acta Oncol. 1990;29(2):129-35 [2334566.001]
  • [Cites] Acta Oncol. 1989;28(6):807-10 [2611034.001]
  • [Cites] Aust N Z J Med. 1978 Dec;8(6):630-8 [285684.001]
  • [Cites] BMJ. 1988 Oct 15;297(6654):943-8 [3142562.001]
  • [Cites] Acta Pathol Jpn. 1984 Mar;34(2):229-39 [6331061.001]
  • [Cites] J Clin Oncol. 1984 Oct;2(10):1102-9 [6491696.001]
  • [Cites] Hum Pathol. 1983 Apr;14(4):368-72 [6832775.001]
  • [Cites] Hum Pathol. 1995 Aug;26(8):873-9 [7635449.001]
  • [Cites] Breast Cancer Res Treat. 1995 Aug;35(2):201-10 [7647342.001]
  • [Cites] Semin Diagn Pathol. 1994 Aug;11(3):208-14 [7831532.001]
  • [Cites] Anal Quant Cytol Histol. 1994 Jun;16(3):203-10 [7916848.001]
  • [Cites] Surgery. 1994 Oct;116(4):605-8; discussion 608-9 [7940156.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):23-33 [8083119.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):156-61 [8100443.001]
  • [Cites] Hematol Oncol Clin North Am. 1994 Feb;8(1):73-100 [8150784.001]
  • [Cites] Am J Surg. 1993 Mar;165(3):307-11 [8447534.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2894-904 [9256133.001]
  • [Cites] AJR Am J Roentgenol. 1998 Jan;170(1):97-104 [9423608.001]
  • [Cites] Stem Cells. 1998;16(6):413-28 [9831867.001]
  • [Cites] Oncol Rep. 1999 Jan-Feb;6(1):135-8 [9864416.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):2011-7 [10213514.001]
  • [Cites] Ontogenez. 1999 Mar-Apr;30(2):130-3 [10368823.001]
  • [Cites] Mod Pathol. 1999 Aug;12(8):827-34 [10463486.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Oct;8(10):855-61 [10548312.001]
  • [Cites] Oncol Rep. 2000 Mar-Apr;7(2):295-8 [10671674.001]
  • [Cites] Am J Surg. 2000 Feb;179(2):81-5 [10773138.001]
  • [Cites] J Clin Pathol. 2000 Sep;53(9):688-96 [11041059.001]
  • [Cites] Int J Cancer. 2002 Apr 10;98(5):754-60 [11920647.001]
  • [Cites] Oncol Rep. 2002 Sep-Oct;9(5):1053-7 [12168072.001]
  • [Cites] Breast Cancer Res Treat. 2002 Dec;76(3):221-36 [12462383.001]
  • [Cites] Eur J Cancer. 2003 Mar;39(5):622-30 [12628841.001]
  • [Cites] Jpn J Clin Oncol. 2003 Feb;33(2):61-7 [12629055.001]
  • [Cites] Oncol Rep. 2003 Sep-Oct;10(5):1321-8 [12883701.001]
  • [Cites] Endocr Rev. 1992 Feb;13(1):3-17 [1313356.001]
  • [Cites] Br J Cancer. 1992 Oct;66(4):610-3 [1419596.001]
  • [Cites] Curr Opin Obstet Gynecol. 2004 Feb;16(1):49-55 [15128008.001]
  • [Cites] Breast Cancer Res Treat. 1998;52(1-3):305-19 [10066089.001]
  • (PMID = 17892570.001).
  • [ISSN] 1477-3163
  • [Journal-full-title] Journal of carcinogenesis
  • [ISO-abbreviation] J Carcinog
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2169224
  •  go-up   go-down


75. Ferrigno R, Novaes PE, Silva ML, Nishimoto IN, Nakagawa WT, Rossi BM, Ferreira Fde O, Lopes A: Neoadjuvant radiochemotherapy in the treatment of fixed and semi-fixed rectal tumors. Analysis of results and prognostic factors. Radiat Oncol; 2006;1:5
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To report the retrospective analysis of patients with locally advanced rectal cancer treated with neodjuvant radiochemotherapy.
  • In 71 patients (70.3%) the primary tumor was located up to 6 cm from the anal verge and in 30 (29.7%) from 6.5 cm to 10 cm.
  • Age, gender, tumor fixation, tumor distance from the anal verge, clinical response, surgical technique, and postoperative TNM stage were the prognostic factors analyzed for overall survival (OS), disease-free survival (DFS), and local control (LC) at five years.
  • Patients with tumors more than 6 cm above the anal verge had better LC (93% Vs 69%; p = 0.04).
  • The postoperative TNM stage was a significant factor for DFS (I:64.1%, II:69.6%, III:35.2%, IV:11.1%; p < 0.001) and for LC (I:75.7%, II: 92.9%, III:54.1%, IV:100%; p = 0.005).

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Radiother. 2004 Oct;8(5):297-304 [15561595.001]
  • [Cites] Dis Colon Rectum. 2004 Nov;47(11):1798-807 [15622571.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):665-77 [15708244.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1129-35 [15752893.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1847-58 [15774778.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1371-7 [15817339.001]
  • [Cites] Ann Surg. 2005 May;241(5):829-36; discussion 836-8 [15849519.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2396 [10561302.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):883-8 [10705009.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):713-8 [10837955.001]
  • [Cites] JAMA. 2000 Aug 23-30;284(8):1008-15 [10944647.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):843-56 [11020583.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1075-80 [11072165.001]
  • [Cites] Ann Surg Oncol. 2000 Dec;7(10):727-31 [11129419.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1779-86 [11251009.001]
  • [Cites] Ann Surg Oncol. 2001 Mar;8(2):163-9 [11258782.001]
  • [Cites] Am J Clin Oncol. 2001 Apr;24(2):107-12 [11319280.001]
  • [Cites] Ann Surg Oncol. 2001 May;8(4):311-8 [11352304.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):659-63 [11395233.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):176-83 [11516868.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):896-902 [11550163.001]
  • [Cites] Ann Surg Oncol. 2001 Dec;8(10):801-6 [11776494.001]
  • [Cites] J Am Coll Surg. 2002 Feb;194(2):131-5; discussion 135-6 [11848629.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):294-303 [11872273.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):493-8 [11923604.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):664-74 [12062610.001]
  • [Cites] Ann Surg Oncol. 2002 Jul;9(6):568-73 [12095973.001]
  • [Cites] Ann Surg. 2002 Jul;236(1):75-81 [12131088.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1460-5 [12459370.001]
  • [Cites] Cancer. 2003 Jan 15;97(2):517-24 [12518377.001]
  • [Cites] Dis Colon Rectum. 2003 Feb;46(2):192-202 [12576893.001]
  • [Cites] Dis Colon Rectum. 2003 Mar;46(3):298-304 [12626903.001]
  • [Cites] Dis Colon Rectum. 2003 Apr;46(4):448-53 [12682535.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):84-9 [12909219.001]
  • [Cites] Dis Colon Rectum. 2003 Sep;46(9):1189-93 [12972962.001]
  • [Cites] Dis Colon Rectum. 2003 Sep;46(9):1194-9 [12972963.001]
  • [Cites] Semin Surg Oncol. 2003;21(4):261-4 [14648784.001]
  • [Cites] Semin Surg Oncol. 2003;21(4):265-70 [14648785.001]
  • [Cites] Eur J Cancer. 2004 Jan;40(2):219-24 [14728936.001]
  • [Cites] Tumori. 2004 May-Jun;90(3):303-9 [15315310.001]
  • [Cites] Dis Colon Rectum. 2004 Aug;47(8):1323-30 [15484346.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] J Clin Oncol. 1992 Aug;10(8):1218-24 [1634912.001]
  • [Cites] Cancer. 1993 Jun 1;71(11):3486-92 [8490898.001]
  • [Cites] Oncology (Williston Park). 1989 May;3(5):137-42; discussion 142, 146-8 [2577881.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):169-75 [8083110.001]
  • [Cites] Radiother Oncol. 1994 Aug;32(2):116-23 [7972904.001]
  • [Cites] Cancer Invest. 1995;13(1):96-107 [7834479.001]
  • [Cites] Cancer. 1995 May 1;75(9):2269-75 [7712435.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1409-16 [7751886.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1473-5 [7635791.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):281-7 [9069298.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):289-95 [9069299.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14):980-7 [9091798.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):893-900 [15936575.001]
  • [Cites] Semin Oncol. 1995 Dec;22(6):611-24 [8539636.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jul 15;35(5):1039-48 [8751414.001]
  • [Cites] Cancer. 1996 Sep 1;78(5):968-76 [8780533.001]
  • [Cites] Ann Surg Oncol. 1996 Sep;3(5):419-20 [8876881.001]
  • [Cites] Oncology (Williston Park). 1996 Nov;10(11):1701-8, 1713-4; discussion 1714-18 [8953589.001]
  • [Cites] Lancet. 1996 Dec 14;348(9042):1605-10 [8961989.001]
  • [Cites] Dis Colon Rectum. 1997 Feb;40(2):131-9 [9075745.001]
  • [Cites] Radiographics. 1997 May-Jun;17(3):609-26 [9153700.001]
  • [Cites] Radiology. 1997 Aug;204(2):533-8 [9240549.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Feb 1;40(3):569-74 [9486606.001]
  • [Cites] Ann Surg Oncol. 1998 Mar;5(2):113-8 [9527263.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Mar 15;40(5):1067-75 [9539561.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):51-7 [9747819.001]
  • [Cites] Ann Surg. 1999 Apr;229(4):493-7 [10203081.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1027-38 [10421535.001]
  • (PMID = 16722598.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC1459184
  • [General-notes] NLM/ Original DateCompleted: 20060619
  •  go-up   go-down


76. Yuan J, Ku GY, Gallardo HF, Orlandi F, Manukian G, Rasalan TS, Xu Y, Li H, Vyas S, Mu Z, Chapman PB, Krown SE, Panageas K, Terzulli SL, Old LJ, Houghton AN, Wolchok JD: Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer Immun; 2009 Jun 05;9:5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients had no evidence of disease; 10 (53%) had stage III disease, 3 each (16%) had stage IIB and IV disease, 2 (11%) had choroidal and 1 (5%) had anal mucosal involvement.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gene Ther. 2003 Sep;10(20):1754-65 [12939642.001]
  • [Cites] Surgery. 2000 Aug;128(2):273-80 [10923004.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Jul;77(7):4260-4 [6933476.001]
  • [Cites] J Exp Med. 1982 Dec 1;156(6):1755-66 [7175440.001]
  • [Cites] J Invest Dermatol. 1988 Apr;90(4):459-66 [3280698.001]
  • [Cites] J Immunol. 1995 Apr 15;154(8):3961-8 [7706734.001]
  • [Cites] J Exp Med. 1995 Aug 1;182(2):459-65 [7543139.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2879-83 [8610135.001]
  • [Cites] Science. 1996 Jul 19;273(5273):352-4 [8662521.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4749-57 [8840994.001]
  • [Cites] J Immunother. 1997 Jan;20(1):15-25 [9101410.001]
  • [Cites] Am J Pathol. 1997 Jun;150(6):2143-52 [9176405.001]
  • [Cites] J Clin Invest. 1998 Sep 15;102(6):1258-64 [9739060.001]
  • [Cites] J Immunol. 1999 May 15;162(10):5813-20 [10229815.001]
  • [Cites] Surgery. 1999 Aug;126(2):112-20 [10455872.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8114-21 [16299244.001]
  • [Cites] Cancer Immun. 2006;6:8 [16626110.001]
  • [Cites] Vaccine. 2006 May 22;24(21):4582-5 [16188351.001]
  • [Cites] Cytotherapy. 2006;8(5):498-508 [17050255.001]
  • [Cites] J Immunol. 2007 Apr 1;178(7):4112-9 [17371966.001]
  • [Cites] J Exp Med. 2007 Jun 11;204(6):1405-16 [17535971.001]
  • [Cites] Mol Ther. 2007 Nov;15(11):2044-50 [17726460.001]
  • [Cites] Eur J Immunol. 2008 Feb;38(2):350-63 [18200635.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Oncologist. 2008;13 Suppl 4:2-9 [19001145.001]
  • [Cites] Oncologist. 2008;13 Suppl 4:10-5 [19001146.001]
  • [Cites] Mol Ther. 2008 Dec;16(12):2022-9 [18797450.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20410-5 [19074257.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):967-72 [12006508.001]
  • [Cites] J Exp Med. 1999 Dec 6;190(11):1717-22 [10587362.001]
  • [Cites] J Immunol. 1999 Dec 15;163(12):6867-75 [10586088.001]
  • [Cites] Annu Rev Immunol. 2004;22:745-63 [15032595.001]
  • (PMID = 19496531.001).
  • [ISSN] 1424-9634
  • [Journal-full-title] Cancer immunity
  • [ISO-abbreviation] Cancer Immun.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA033049-24; United States / NCI NIH HHS / CA / CA033049-24; United States / NCI NIH HHS / CA / P01CA33049; United States / NCI NIH HHS / CA / P01 CA033049; United States / NCI NIH HHS / CA / R01 CA056821; United States / NCCIH NIH HHS / AT / P50AT002779
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / HLA-A2 Antigen; 0 / Membrane Glycoproteins; 0 / PMEL protein, human; 0 / Peptides; 0 / Si protein, mouse; 0 / Vaccines, DNA; 0 / gp100 Melanoma Antigen; 0 / gp100(280-288) melanoma antigen peptide
  • [Other-IDs] NLM/ NIHMS201057; NLM/ PMC2888533
  •  go-up   go-down


77. Hohenberger W, Merkel S, Matzel K, Bittorf B, Papadopoulos T, Göhl J: The influence of abdomino-peranal (intersphincteric) resection of lower third rectal carcinoma on the rates of sphincter preservation and locoregional recurrence. Colorectal Dis; 2006 Jan;8(1):23-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of abdomino-peranal (intersphincteric) resection of lower third rectal carcinoma on the rates of sphincter preservation and locoregional recurrence.
  • PATIENTS AND METHODS: The data of 476 patients with a carcinoma in the lower third of the rectum who underwent primary treatment for stage I-III disease by low anterior resection, abdomino-peranal (intersphincteric) resection or abdominoperineal excision between 1985 and 2001 were analysed.
  • The cancer-related 5-year survival rate was not altered by intersphincteric resection.
  • [MeSH-major] Anal Canal / surgery. Carcinoma / surgery. Colectomy / methods. Neoplasm Recurrence, Local / epidemiology. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16519634.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


78. Wrobel K, Wrobel K, Caruso JA: Epigenetics: an important challenge for ICP-MS in metallomics studies. Anal Bioanal Chem; 2009 Jan;393(2):481-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At the early stage of instrumental development, total concentration was assessed in a variety of samples, yielding results, among others, for environmental, biological, and clinical samples.
  • Among a variety of epigenetic factors, essential nutrients, but also environmental toxins, have been shown to affect DNA methylation, modification of histone proteins, and RNA interference, all of them being implicated in cancer, cardiovascular disease, and several inherited conditions.
  • In this Trends article, the basic epigenetic concepts are introduced, followed by the early applications of ICP-MS classified as: (i) detection of (31)P as a natural element tag for DNA, (ii) analysis of DNA adducts with metal-based drugs, (iii) element species as epigenetic factors.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • Hazardous Substances Data Bank. PHOSPHORUS, ELEMENTAL .
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18979091.001).
  • [ISSN] 1618-2650
  • [Journal-full-title] Analytical and bioanalytical chemistry
  • [ISO-abbreviation] Anal Bioanal Chem
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Metals; 0 / Pharmaceutical Preparations; 27YLU75U4W / Phosphorus; 9007-49-2 / DNA; H6241UJ22B / Selenium; N712M78A8G / Arsenic
  • [Number-of-references] 38
  •  go-up   go-down


79. El Badry AA, El-Fadle AA, El-Balshy AL: Tissue inhibitor of matrix metalloproteinase-2 in nasopharyngeal carcinoma. MedGenMed; 2007;9(3):3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue inhibitor of matrix metalloproteinase-2 in nasopharyngeal carcinoma.
  • The present study was designed to clarify the role of TIMP-2 in nasopharyngeal carcinoma (NPC) patients and to evaluate its importance relative to clinicopathologic parameters.
  • Clinically, in accordance with TNM classification (T: tumor size, N: lymph node involvement, M: distant metastasis), 8 cases were diagnosed as stage II, 12 as stage III, and 10 cases as stage IV; however, pathologic typing with use of the World Health Organization (WHO) classification revealed the presence of 9 specimens of squamous cell carcinoma (WHO type 1), 6 cases of nonkeratinizing carcinoma (WHO type 2), and 15 cases of undifferentiated carcinoma (WHO type 3).
  • In addition, there was a significant positive correlation between TIMP-2 protein positivity and either the clinical staging or the histopathologic typing (P < .01) using Chi-square test (x(2)), suggesting that TIMP-2 can be used as a marker of the severity of NPC.Accordingly, we can assume that TIMP-2 may play a role in regional lymph node and/or distant metastasis and in progression of squamous cell carcinoma.
  • [MeSH-major] Carcinoma / chemistry. Carcinoma / enzymology. Nasopharyngeal Neoplasms / chemistry. Nasopharyngeal Neoplasms / enzymology. Tissue Inhibitor of Metalloproteinase-2 / analysis

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1999 Nov;189(3):300-8 [10547590.001]
  • [Cites] Am J Clin Pathol. 1993 Jan;99(1):18-23 [8422010.001]
  • [Cites] Adv Exp Med Biol. 2000;465:469-83 [10810650.001]
  • [Cites] Br J Cancer. 2000 Jul;83(2):215-8 [10901373.001]
  • [Cites] Hum Pathol. 2000 Aug;31(8):895-904 [10987249.001]
  • [Cites] Int J Oncol. 2000 Dec;17(6):1099-105 [11078794.001]
  • [Cites] Int J Cancer. 2001 Jan 20;95(1):44-50 [11241310.001]
  • [Cites] J Med Invest. 2001 Feb;48(1-2):31-43 [11286015.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):813-20 [11448356.001]
  • [Cites] Int J Colorectal Dis. 2001 Jun;16(3):133-40 [11459286.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3113-9 [11595703.001]
  • [Cites] Mod Pathol. 2002 Jan;15(1):26-34 [11796838.001]
  • [Cites] Isr Med Assoc J. 2002 Apr;4(4):247-51 [12001695.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 28;99(11):7414-9 [12032297.001]
  • [Cites] Ai Zheng. 2002 Jan;21(1):91-4 [12500407.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Otolaryngol Head Neck Surg. 1983 Jun;91(3):255-62 [6308537.001]
  • [Cites] J Biol Chem. 1989 Oct 15;264(29):17374-8 [2793861.001]
  • [Cites] Int J Cancer. 1994 Nov 1;59(3):339-44 [7927938.001]
  • [Cites] J Biol Chem. 1995 Mar 10;270(10):5331-8 [7890645.001]
  • [Cites] Cancer Res. 1996 Apr 1;56(7):1654-9 [8603416.001]
  • [Cites] FEBS Lett. 1996 May 6;385(3):238-40 [8647259.001]
  • [Cites] Cancer Res. 1996 Jun 15;56(12):2707-10 [8665498.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):139-44 [8988738.001]
  • [Cites] Eur J Cell Biol. 1997 Oct;74(2):111-22 [9352216.001]
  • [Cites] Nat Genet. 1997 Dec;17(4):439-44 [9398846.001]
  • [Cites] Br J Cancer. 1998 Feb;77(4):650-5 [9484825.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1359-66 [9529029.001]
  • [Cites] Clin Cancer Res. 1997 Sep;3(9):1623-8 [9815852.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):467-73 [9927064.001]
  • [Cites] Anticancer Res. 1999 Mar-Apr;19(2C):1589-92 [10365151.001]
  • [Cites] J Biol Chem. 1999 Jul 30;274(31):21491-4 [10419448.001]
  • [Cites] Head Neck. 1999 Oct;21(7):627-38 [10487950.001]
  • [Cites] J Biol Chem. 1991 Sep 5;266(25):16485-90 [1653238.001]
  • [Cites] Anticancer Res. 2000 Mar-Apr;20(2B):1085-91 [10810401.001]
  • (PMID = 18092010.001).
  • [ISSN] 1531-0132
  • [Journal-full-title] MedGenMed : Medscape general medicine
  • [ISO-abbreviation] MedGenMed
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2
  • [Other-IDs] NLM/ PMC2100075
  •  go-up   go-down


80. Liu KJ, Brock MV, Shih IeM, Wang TH: Decoding circulating nucleic acids in human serum using microfluidic single molecule spectroscopy. J Am Chem Soc; 2010 Apr 28;132(16):5793-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among these markers, DNA fragment size has shown promise for discerning the source of CNA molecules in cancer and prenatal diagnostics.
  • First, single molecule sizing was performed on lambda Hind III digest DNA to obtain a size calibration curve.
  • Finally, DNA sizing analysis was performed on serum samples from both early and late stage lung cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2006;34(5):e35 [16517937.001]
  • [Cites] Nat Mater. 2005 Nov;4(11):826-31 [16379073.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4270-6 [16963729.001]
  • [Cites] Curr Opin Oncol. 2007 Jan;19(1):36-42 [17133110.001]
  • [Cites] Biochim Biophys Acta. 2007 Jan;1775(1):181-232 [17137717.001]
  • [Cites] FEBS Lett. 2007 Mar 6;581(5):795-9 [17289032.001]
  • [Cites] Clin Cancer Res. 2008 Jul 1;14(13):4141-5 [18593992.001]
  • [Cites] Biophys J. 2008 Sep 15;95(6):2964-75 [18515376.001]
  • [Cites] Nat Med. 2008 Sep;14(9):985-90 [18670422.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19920-5 [19060211.001]
  • [Cites] Genome Res. 2009 Aug;19(8):1455-61 [19443857.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1659-65 [11245480.001]
  • [Cites] Anal Chem. 2002 Mar 15;74(6):1415-22 [11922312.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3966-8 [12873992.001]
  • [Cites] Clin Chem. 2004 Jan;50(1):88-92 [14709639.001]
  • [Cites] Cytometry A. 2004 Aug;60(2):125-34 [15290713.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):11-3 [9874762.001]
  • [Cites] JAMA. 2005 Feb 16;293(7):843-9 [15713774.001]
  • [Cites] J Am Chem Soc. 2005 Apr 20;127(15):5354-9 [15826173.001]
  • [Cites] Clin Chim Acta. 2006 Jan;363(1-2):187-96 [16126188.001]
  • [Cites] Clin Chem. 2006 Jun;52(6):1062-9 [16723681.001]
  • (PMID = 20364832.001).
  • [ISSN] 1520-5126
  • [Journal-full-title] Journal of the American Chemical Society
  • [ISO-abbreviation] J. Am. Chem. Soc.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21-CA120742-01; United States / NCI NIH HHS / CA / R21 CA120742-01A2; United States / NCI NIH HHS / CA / U54 CA151838-01; United States / NIAID NIH HHS / AI / U54-AI057168-06; United States / NCI NIH HHS / CA / P50 CA058184-17; United States / NCI NIH HHS / CA / P50 CA058184; United States / NCI NIH HHS / CA / U54 CA151838; United States / NCI NIH HHS / CA / R21 CA120742; United States / NCI NIH HHS / CA / R21 CA120742-02; United States / NIAID NIH HHS / AI / U54 AI057168
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indicators and Reagents; 9007-49-2 / DNA; EC 3.1.21.- / Deoxyribonuclease HindIII
  • [Other-IDs] NLM/ NIHMS194324; NLM/ PMC3273337
  •  go-up   go-down


81. Filippi L, Cavallaro G, Fiorini P, Daniotti M, Benedetti V, Cristofori G, Araimo G, Ramenghi L, La Torre A, Fortunato P, Pollazzi L, la Marca G, Malvagia S, Bagnoli P, Ristori C, Dal Monte M, Bilia AR, Isacchi B, Furlanetto S, Tinelli F, Cioni G, Donzelli G, Osnaghi S, Mosca F: Study protocol: safety and efficacy of propranolol in newborns with Retinopathy of Prematurity (PROP-ROP): ISRCTN18523491. BMC Pediatr; 2010 Nov 18;10:83
Hazardous Substances Data Bank. PROPRANOLOL HYDROCHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS/DESIGN: Preterm newborns (gestational age at birth lower than 32 weeks) with stage 2 ROP (zone II-III without plus) will be randomized, according to their gestational age, to receive propranolol added to standard treatment (treatment adopted by the ETROP Cooperative Group) or standard treatment alone.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Archivio Istituzionale della Ricerca Unimi. Full text from AIR - Univ. Milan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Retina. 2008 Mar;28(3 Suppl):S19-25 [18317339.001]
  • [Cites] Br J Ophthalmol. 2008 May;92(5):689-93 [18408080.001]
  • [Cites] Retina. 2008 Jun;28(6):831-8 [18536599.001]
  • [Cites] N Engl J Med. 2008 Jun 12;358(24):2649-51 [18550886.001]
  • [Cites] Prog Retin Eye Res. 2008 Jul;27(4):331-71 [18653375.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5177-82 [18708611.001]
  • [Cites] Growth Factors. 2008 Dec;26(6):325-30 [19021032.001]
  • [Cites] J Pharm Biomed Anal. 2008 Dec 15;48(5):1392-6 [18980824.001]
  • [Cites] Brain Behav Immun. 2009 Feb;23(2):267-75 [18996182.001]
  • [Cites] Pediatrics. 2009 Mar;123(3):e484-9 [19221153.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2009 Aug;297(2):R258-64 [19458283.001]
  • [Cites] Oncol Rep. 2009 Oct;22(4):825-30 [19724861.001]
  • [Cites] Nat Med. 1995 Oct;1(10):1024-8 [7489357.001]
  • [Cites] Arch Ophthalmol. 1996 Feb;114(2):150-4 [8573016.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):4604-13 [8756616.001]
  • [Cites] Arch Ophthalmol. 1996 Oct;114(10):1219-28 [8859081.001]
  • [Cites] Endocr Rev. 1997 Feb;18(1):4-25 [9034784.001]
  • [Cites] Growth Factors. 1998;16(1):1-9 [9777366.001]
  • [Cites] J Biol Chem. 1999 Jun 4;274(23):16349-54 [10347193.001]
  • [Cites] Development. 2005 Apr;132(8):1855-62 [15790963.001]
  • [Cites] Pediatrics. 2005 Jul;116(1):15-23 [15995025.001]
  • [Cites] Auton Neurosci. 2005 Aug 31;121(1-2):33-9 [15961351.001]
  • [Cites] Circ Res. 2005 Nov 25;97(11):1182-9 [16239589.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):369-75 [16428474.001]
  • [Cites] Arch Ophthalmol. 2006 Feb;124(2):199-202 [16476889.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2744-9 [16381019.001]
  • [Cites] Nat Med. 2006 Aug;12(8):939-44 [16862152.001]
  • [Cites] Br J Ophthalmol. 2006 Nov;90(11):1378-82 [16914473.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10357-64 [17079456.001]
  • [Cites] Eur J Pharmacol. 2006 Dec 28;553(1-3):54-60 [17070516.001]
  • [Cites] Epilepsia. 2009 Dec;50(12):2658-62 [19682026.001]
  • [Cites] J Pediatr. 2010 Apr;156(4):550-5 [20056237.001]
  • [Cites] Arch Ophthalmol. 2010 Jun;128(6):663-71 [20385926.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2010 Jul;51(7):3709-13 [20181841.001]
  • [Cites] Pediatrics. 2009 Sep;124(3):e423-31 [19706583.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2011 Jan;52(1):155-70 [20739470.001]
  • [Cites] Pediatrics. 2003 Nov;112(5):1016-20 [14595040.001]
  • [Cites] Arch Ophthalmol. 2003 Dec;121(12):1684-94 [14662586.001]
  • [Cites] Physiology (Bethesda). 2004 Aug;19:176-82 [15304631.001]
  • [Cites] Pediatr Res. 2004 Nov;56(5):768-74 [15319463.001]
  • [Cites] Pediatrics. 1977 Nov;60(5):655-68 [578921.001]
  • [Cites] Am J Dis Child. 1980 Jul;134(7):707-8 [7395835.001]
  • [Cites] Nat Med. 1999 Dec;5(12):1390-5 [10581081.001]
  • [Cites] Pediatrics. 2000 Feb;105(2):295-310 [10654946.001]
  • [Cites] J Biol Chem. 2000 May 5;275(18):13802-11 [10788502.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2866-9 [11306460.001]
  • [Cites] FASEB J. 2001 May;15(7):1215-7 [11344092.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 8;98(10):5804-8 [11331770.001]
  • [Cites] Pharmacol Rev. 2001 Jun;53(2):319-56 [11356987.001]
  • [Cites] EMBO J. 2001 Jun 1;20(11):2768-78 [11387210.001]
  • [Cites] Arch Ophthalmol. 2001 Aug;119(8):1129-33 [11483078.001]
  • [Cites] Childs Nerv Syst. 2002 Apr;18(3-4):137-41 [11981620.001]
  • [Cites] Ophthalmology. 2002 May;109(5):928-34; discussion 935 [11986099.001]
  • [Cites] Ophthalmology. 2002 May;109(5):936-41 [11986101.001]
  • [Cites] Front Biosci. 2003 May 1;8:d1030-43 [12700061.001]
  • [Cites] J Biol Chem. 2003 Jun 6;278(23):20681-6 [12670949.001]
  • [Cites] Breast Cancer Res Treat. 2003 Jul;80(1):63-70 [12889599.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4514-21 [14555525.001]
  • [Cites] Am J Dis Child. 1980 Sep;134(9):819-20 [6998280.001]
  • [Cites] Pediatrics. 1984 Jan;73(1):82-96 [6419199.001]
  • [Cites] Pediatrics. 1987 May;79(5):663-9 [3575019.001]
  • [Cites] Hypertension. 1988 Mar;11(3 Pt 2):II21-9 [2895072.001]
  • [Cites] Ophthalmology. 1991 Nov;98(11):1628-40 [1800923.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):843-5 [1279431.001]
  • [Cites] Endocrinology. 1993 Aug;133(2):848-59 [7688292.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1994 Jan;35(1):101-11 [7507904.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):905-9 [7846076.001]
  • [Cites] Circ Res. 1995 May;76(5):758-66 [7728992.001]
  • [Cites] Exp Eye Res. 2007 Jan;84(1):75-81 [17074321.001]
  • [Cites] Arch Ophthalmol. 2006 Dec;124(12):1711-8 [17159030.001]
  • [Cites] Neurochem Int. 2007 Jan;50(1):211-8 [17014930.001]
  • [Cites] Angiogenesis. 2007;10(2):133-40 [17332988.001]
  • [Cites] Ophthalmic Surg Lasers Imaging. 2007 May-Jun;38(3):233-7 [17552391.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2007 Nov;48(11):5276-81 [17962483.001]
  • [Cites] Early Hum Dev. 2008 Feb;84(2):107-13 [17513071.001]
  • [Cites] Early Hum Dev. 2008 Feb;84(2):77-82 [18234457.001]
  • (PMID = 21087499.001).
  • [ISSN] 1471-2431
  • [Journal-full-title] BMC pediatrics
  • [ISO-abbreviation] BMC Pediatr
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN18523491; ClinicalTrials.gov/ NCT01079715
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists; 9Y8NXQ24VQ / Propranolol
  • [Other-IDs] NLM/ PMC2993687
  •  go-up   go-down


82. Balik E, Eren T, Bulut T, Büyükuncu Y, Bugra D, Yamaner S: Surgical approach to extensive hidradenitis suppurativa in the perineal/perianal and gluteal regions. World J Surg; 2009 Mar;33(3):481-7
MedlinePlus Health Information. consumer health - Hidradenitis Suppurativa.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we present our experience with stage III extensive hidradenitis suppurativa cases, including our treatment methods and patient outcomes.
  • Squamous cell carcinoma was diagnosed in the specimens of one patient treated with total excision followed by the application of a rotation flap.
  • The cancer recurred after 6 months in the perianal region and immediate abdominoperineal resection was performed.
  • Despite the low incidence of accompanying squamous cell carcinoma, it is the most serious complication.
  • [MeSH-minor] Adult. Aged. Anal Canal. Buttocks. Humans. Longitudinal Studies. Male. Middle Aged. Perineum. Retrospective Studies. Skin Transplantation. Treatment Outcome. Wound Healing / physiology. Young Adult

  • Genetic Alliance. consumer health - Hidradenitis Suppurativa.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] World J Surg. 2010 Apr;34(4):861-2; author reply 863 [20012284.001]
  • [CommentIn] World J Surg. 2009 Mar;33(3):488 [19137367.001]
  • [Cites] Arch Dermatol. 1982 Feb;118(2):101-2 [7059208.001]
  • [Cites] Plast Reconstr Surg. 1976 Jul;58(1):44-7 [935277.001]
  • [Cites] Dis Colon Rectum. 1990 Sep;33(9):731-4 [2390907.001]
  • [Cites] J Natl Med Assoc. 1982 Oct;74(10):999-1003 [7143473.001]
  • [Cites] Surg Clin North Am. 1994 Dec;74(6):1317-25 [7985067.001]
  • [Cites] Dis Colon Rectum. 1983 Oct;26(10):669-76 [6884157.001]
  • [Cites] J Surg Oncol. 1982 Jan;19(1):25-6 [7057641.001]
  • [Cites] J Am Acad Dermatol. 1984 Sep;11(3):500-2 [6384295.001]
  • [Cites] J Am Acad Dermatol. 2000 Jan;42(1 Pt 1):89-91 [10607326.001]
  • [Cites] Dis Colon Rectum. 1970 Nov-Dec;13(6):441-3 [5501399.001]
  • [Cites] Surgery. 2005 Oct;138(4):734-40; discussion 740-1 [16269303.001]
  • [Cites] Br J Dermatol. 2000 May;142(5):947-53 [10809853.001]
  • [Cites] Int J Colorectal Dis. 1998;13(4):164-8 [9810520.001]
  • [Cites] Am Fam Physician. 2005 Oct 15;72(8):1547-52 [16273821.001]
  • [Cites] Ann R Coll Surg Engl. 1997 Mar;79(2):83-9 [9135232.001]
  • [Cites] J Am Acad Dermatol. 1996 Jun;34(6):994-9 [8647993.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2000 Sep;14(5):389-92 [11305381.001]
  • [Cites] Dis Colon Rectum. 2003 Jul;46(7):944-9 [12847371.001]
  • [Cites] Ann Plast Surg. 1987 Jan;18(1):71-3 [3827135.001]
  • [Cites] Br J Surg. 1992 Sep;79(9):863-6 [1422743.001]
  • [Cites] Am Surg. 1970 Jun;36(6):331-4 [4909944.001]
  • [Cites] Br J Dermatol. 2002 Mar;146(3):409-13 [11952540.001]
  • [Cites] Histopathology. 1993 Aug;23(2):111-5 [8406382.001]
  • [Cites] J Am Acad Dermatol. 1988 May;18(5 Pt 1):1103-7 [3385029.001]
  • [Cites] Br J Plast Surg. 2000 Jul;53(5):434-6 [10876285.001]
  • [Cites] Am J Surg. 1982 Dec;144(6):668-70 [7149125.001]
  • [Cites] Int J Colorectal Dis. 1993 Sep;8(3):117-9 [8245664.001]
  • [Cites] Br J Plast Surg. 2003 Jul;56(5):451-61 [12890458.001]
  • [Cites] Br J Dermatol. 1998 Nov;139(5):906-10 [9892965.001]
  • (PMID = 19067039.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement